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Summary 
Inhibition of the ubiquitin proteasome system (UPS) has been postulated to play a key 
role in the pathogenesis of neurodegenerative diseases such as Alzheimer’s disease. 
On the other hand, studies have also shown that proteasome inhibition can induce a 
neuroprotective rise in the levels of various heat shock proteins (HSPs). This study 
examines the global gene expression of primary neurons in response to treatment with 
the proteasome inhibitor, lactacystin and identifies differentially expressed genes that 
may play a role in the regulation of proteasome inhibitor-mediated apoptosis. Our 
results show an upregulation of genes involved in the UPS, oxidative stress response, 
HSP family, cell cycle regulation and inflammatory response, amongst others. 
Together, these data suggest an initial neuroprotective pathway involving HSPs, 
antioxidants and cell cycle inhibitors, followed by a pro-apoptotic response mediated 
by inflammation, oxidative stress and possibly, aberrant activation of cell cycle 
proteins. Further studies were carried out to investigate the role of selected 
differentially expressed genes in the regulation of neuronal apoptosis. These include a 
novel heat shock protein, heat shock protein 22 (HSP22), annexin A3 (Anxa3) and a 
novel gene, neoplastic progression 3 (Npn3). 
 
The upregulation of HSP22 was specific towards proteasome inhibitor-mediated cell 
death and did not take place when cell death was induced by other drugs. A pIRES2-
EGFP-HSP22 clone was generated and HSP22 was found to exhibit a small 
neuroprotective effect against proteasome inhibitor-mediated apoptosis in 
differentiated PC12 cells, protecting against loss of viability by up to 25%. This 
neuroprotective effect was specific towards differentiated neuron-like cells only thus 
suggesting a role for this protein in the regulation of apoptosis in neurons. 
ix 
Anxa3 is a protein whose physiological function is not well understood. A pIRES2-
EGFP-Anxa3 clone was generated and results showed that the upregulation of this 
gene also resulted in a neuroprotective effect against proteasome inhibitor-mediated 
apoptosis, protecting against loss of viability by up to 20%. This effect also appeared 
to be specific towards neuron-like differentiated cells. 
 
Npn3 is a novel gene in this context and it is of interest to further explore its possible 
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1.1 Neurodegenerative diseases 
A common histopathological hallmark of the major neurodegenerative diseases such 
as Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis 
(ALS), Huntington’s disease (HD) and prion diseases is the accumulation of abnormal 
or altered proteins (Ross and Poirier, 2004). As the ubiquitin proteasome system (UPS) 
plays a key role in cellular protein quality control, being involved in the degradation 
of misfolded and abberant proteins, its dysfunction is increasingly considered to be a 
primary mechanism in the neuropathogenesis of these diseases (Halliwell, 2002). 
 
1.1.1 Alzheimer’s disease 
AD is the most common cause of dementia affecting a significant proportion of the 
elderly - about 11% of the US population above age 65 and 50% above  85 (Hof et al., 
1995). This neurodegenerative disease is characterized clinically by progressive loss 
of memory, task performance, speech and recognition of people and objects. There is 
also extensive loss of neurons in the medial temporal lobe of the cortex which spreads 
gradually to other neocortical areas (Vickers et al., 2000). This age-related disease is 
at present incurable and disabling, thus posing an increasingly heavy health, social 
and economic burden worldwide.  
 
The pathological hallmarks of AD include extracellular senile plaques containing 
amyloid-β (Aβ) as the major component and intracellular neurofibrillary tangles 
consisting of hyperphosphorylated microtubule-binding protein tau (Morishima-
Kawashima and Ihara, 2002). Aβ is a 39 to 43-residue protein, existing as Aβ1-40 and 
Aβ1-42. The former is the major species found in vivo while the latter is more 
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hydrophobic, having two additional hydrophobic residues, Ile and Ala. Thus it has a 
greater tendency towards aggregation (Morishima-Kawashima and Ihara, 2002). Both 
Aβ peptides are derived from the sequential proteolytic processing of amyloid 
precursor protein (APP), a type-1 membrane protein (Morishima-Kawashima and 
Ihara, 2002). APP first undergoes cleavage by β-secretase, producing a soluble form 
of APP (APPsβ) which is secreted into the lumen, and a membrane-bound C-terminal 
fragment (C-99). C99 is subsequently cleaved by γ-secretase, with the release of the 
40- or 42- amino acid Aβ peptide (Morishima-Kawashima and Ihara, 2002). γ-
secretase is a complex of four enzymes: presenilin (PS), nicastrin, Aph-1 and Pen-2 
(De Strooper, 2003). Mutations in the genes encoding APP, presenilin 1 (PS1) and 
presenilin 2 (PS2) have been linked to familial, early-onset forms of AD. The 
observation that these mutations all result in the increased production and 
accumulation of Aβ1-42 led to the hypothesis that excessive Aβ production is the 
primary cause of AD (de Vrij et al., 2004). 
 
The other important abnormal protein in AD is hyperphosphorylated and abnormally 
folded tau found in the intracellular neurofibrillary tangles. The 55 kDa 
microtubulule-associated protein tau, plays a role in the stabilization of axon 
microtubules, neurite outgrowth, interaction with the actin cytoskeleton, interactions 
with the plasma membrane, enzyme anchoring and intracellular vesicle transport 
regulation (Friedhoff et al., 2000). In AD, tau may dissociate from microtubules due 
to its hyperphosphorylation and accumulate in neurons as paired helical filaments, the 
unit fibrils of neurofibrillary tangles (Morishima-Kawashima and Ihara, 2002). Tangle 
formation appears to be a very important factor in dementia, with tangle pathology 
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correlating better than amyloid plaques with dementia progression in AD in some 
studies (e.g. Giannakopoulos et al., 2003). 
 
Another major component of the neurofibrillary tangles is ubiquitin (Mori et al., 
1987). Within the tangle, N-terminally processed tau was also observed to be 
ubiquitinated (Morishima-Kawashima et al., 1993). These were the initial 
observations suggesting the involvement of the UPS in AD pathogenesis and further 
evidence will be discussed in Section 1.3.  
 
1.1.2 Parkinson’s disease 
Another common neurodegenerative disease is Parkinson’s disease (PD), the most 
common neurodegenerative movement disorder that affects 1 to 2% of individuals 
older than 65 worldwide (de Rijk et al., 2000). Clinically, PD is characterized by 
resting tremor, rigidity and bradykinesia. This is caused by the selective death of 
dopaminergic neurons in  the substantia nigra pars compacta, resulting in the loss of 
striatal dopamine (Lim and Lim, 2003). The pathological hallmark of PD is the 
presence of intracellular protein aggregates known as Lewy bodies in some of the 
surviving dopaminergic neurons (Forno, 1996). While the exact composition of Lewy 
bodies is unknown, a major component is aggregated and ubiquitinated α-synuclein 
(Bossy-Wetzel et al., 2004; Spillantini et al., 1997). These intracytoplasmic inclusions 
have also been found to contain free as well as ubiquitinated protein deposits which 
include parkin, synphilin, neurofilaments and synaptic vesicle proteins (Bossy-Wetzel 
et al., 2004; McNaught et al., 2001). Like AD, there are currently no treatments that 
can prevent or cure this disabling disease.  
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The etiology of PD remains poorly understood. The discovery that the contaminant of 
illicit street drugs, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), caused 
parkinsonian-like symptoms in human substance abusers and in animal models  
suggests an environmental etiology of PD (Bossy-Wetzel et al., 2004) while specific 
genetic defects have been identified in familial forms of PD (Lim and Lim, 2003), 
although collectively these are rare.  It is possible that complex interactions between 
genetic and environmental factors account for most sporadic cases. While nigral 
pathology has been reported to be associated with oxidative stress, mitochondrial 
dysfunction, excitotoxicity and inflammation, various lines of evidence now suggest 
that the dysfunction of the UPS plays a major role in the etiopathogenesis of both 
sporadic and familial PD (McNaught and Olanow, 2003). This is further discussed in 
Section 1.3. 
 
1.1.3 Other neurodegenerative diseases 
Other neurodegenerative diseases besides AD and PD, also have a common feature of 
the accumulation of abnormal or altered proteins (Ross and Poirier, 2004). Examples 
include huntingtin aggregates in HD, Bunina bodies of ALS and prion protein 
aggregates in prion diseases (Taylor et al., 2002). While the association between 
abnormal proteins and neurodegenerative diseases is clear, the mechanism of neuronal 
death in these cases is still unknown.  
 
1.2 The ubiquitin proteasome system  
The UPS is the main machinery involved in the non-lysosomal degradation and 
elimination of short-lived, damaged, abnormal and misfolded intracellular proteins in 
eukaryotic cells (McNaught and Olanow, 2003). This pathway involves two main 
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successive steps: ubiquitination, which is the conjugation of the substrate target 
protein to multiple ubiquitin molecules as a signal for degradation, and the 
degradation of the tagged protein by the 26S proteasome with the release of free and 
reusable ubiquitin molecules (reviewed by Glickman and Ciechanover, 2002). 
 
1.2.1 Ubiquitination 
Ubiquitination is a highly ordered process, involving at least three types of enzymes 
(Fig 1.1). Ubiquitin monomers must first be activated by a ubiquitin-activating 
enzyme (E1). This is an ATP-dependent process resulting in the formation of a high-
energy thiol ester intermediate, E1-S~ubiquitin. Upon activation, ubiquitin is then 
transferred to one of several ubiquitin-conjugating (carrier) enzymes (E2) via another 
high-energy thiol ester intermediate, E2-S~ubiquitin. E2s are conjugating enzymes 
that catalyze the covalent attachment of ubiquitin molecules to target proteins or 
transfer activated ubiquitin to a high energy ubiquitin-protein ligase (E3)~ubiquitin 
intermediate. They are distinguished by a ubiquitin-conjugating (UBC) domain 
necessary for binding of specific E3s and all possess an active site ubiquitin-binding 
cysteine residue. E2s interact with E3s which might or might not have a substrate 
already bound (reviewed by Glickman and Ciechanover, 2002).  
 
E3s are responsible for the specific recognition of the vast range of substrates of the 
UPS and display the greatest variety among the different enzyme components of the 
pathway. They can be classified into two main groups: HECT (homologous to the E6-
AP carboxy-terminus) domain and RING finger-containing E3s. For HECT domain 
E3s, ubiquitin is transferred again from the E2 enzyme to an active site cysteine 
residue on the E3, generating a third high-energy thiol ester intermediate, E3-
7 
S~ubiquitin. After this, it is transferred to the ligase-bound substrate (reviewed by 




Fig 1.1 Enzymes and processes involved in the ubiquitin proteasome pathway 
(from McNaught et al., 2001). 
 
 
On the other hand, RING finger-containing E3s catalyze the direct transfer of 
ubiquitin from the E2 to a free amino residue on the target substrate, usually the ε-
amino of a lysine residue (DeMartino and Slaughter, 1999; Glickman and 
Ciechanover, 2002; Weissman, 2001). These reactions are repeated, enabling the 
successive addition of ubiquitin molecules to lysine 48 of the preceding ubiquitin of 
the target protein to form a polyubiquitin chain (Koegl et al., 1999). A ubiquitin chain 




E3s play a key role in the proteolytic cascade of the UPS as they are involved in 
substrate recognition. A different ligase, often termed E4, is sometimes the enzyme 
involved in subsequent chain elongation, after the first ubiquitin molecule is attached 
to the substrate by one E3 (Weissman, 2001). E4s are a novel protein family 
characterized by a modified version of the RING finger, called the U box domain, 
which mediates the interaction with ubiquitin-conjugated targets (reviewed by de Vrij 
et al., 2004).  
 
1.2.2 Deubiquitination 
The removal of ubiquitin after the ubiquitinated protein is degraded by the 26S 
proteasome is regulated by deubiquitinating enzymes. The two main types of such 
enzymes are the ubiquitin carboxy-terminal hydrolases (UCHs) and ubiquitin-specific 
processing enzymes (UBPs), both of which are thiol proteases (reviewed by 
McNaught et al., 2001). UCHs are small proteins that catalyze the removal of 
carboxy-terminal fusion proteins from ubiquitin and tend to be involved with 
substrates where ubiquitin is conjugated to small peptides (McNaught et al., 2001). 
On the other hand, UBPs are responsible more for the removal of ubiquitin from 
larger proteins and also for cleaving the isopeptide bond linking ubiquitin-ubiquitin or 
ubiquitin-protein (reviewed by de Vrij et al., 2004). 
 
1.2.3 Proteasomes 
Polyubiquitinated proteins are targeted for degradation by the 26S proteasome. This is 
a multicatalytic protease found in the cytoplasm, endoplasmic reticulum, perinuclear 
region and nucleus of eukaryotic cells (Voges et al., 1999).  It is made up of a central 
20S catalytic core and a multisubunit ATPase-containing intracellular PA700 
proteasome activator (19S) (Kisselev and Goldberg, 2001).  
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The 20S proteasome core complex is a barrel-shaped structure made up of four 
heptameric rings aligned axially (refer to Fig 1.2). The two identical outer rings 
contain seven different α-subunits with no catalytic properties while the two identical 
inner rings comprise of different β-subunits, three of which have catalytically active 
threonine residues at their N-termini. These proteolytically active sites catalyze the 
hydrolysis of proteins at the C-terminus of hydrophobic, basic and acidic residues and 
are referred to as the chymotrypsin-like, trypsin-like, and the peptidylglutamyl-
peptide hydrolytic activities respectively (Orlowski and Wilk, 2003). 
 
The 19S regulatory complexes bind to the outer rings at each end of the 20S 
proteasome to form the 26S proteasome (McNaught et al., 2001). This 19S complex is 
made up of a base and a lid. The base consists of two non-ATPase subunits (S1 and 
S2) and six ATPase subunits, some of which attach directly to the α-ring of the 20S 
complex and are thought to be involved in the opening of the central channel, as well 
as the unfolding of substrates and their translocation into the 20S channel (reviewed 
by de Vrij et al., 2004). On the other hand, the lid of the 19S complex is made up of 
eight non-ATPase subunits and while their functions are still undetermined, they are 
essential for the proteolysis of ubiquitinated proteins (reviewed by de Vrij et al., 
2004).  The lid is thought to strongly bind to the polyubiquitin chain and to cleave it 



















Fig 1.2 Composition of the 26S proteasome.  
 
The 26S proteasome consists of a 20S proteasome capped by 19S regulatory 
complexes at both ends (adapted from McNaught et al., 2001). 
 
 
Free 20S proteasomes are the major portion of the total amount of proteasomes 
present in cells. Studies have shown that it is this proteasome form that is responsible 
for the ubiquitin-independent proteolysis of natural unfolded proteins, some short-
lived regulatory proteins and oxidatively damaged, misfolded or mutated proteins 
(Orlowski and Wilk, 2003). 
 
The catalytic mechanism of the proteasome is unique as unlike any other protease, all 
their proteolytic sites utilize N-terminal threonines of β subunits as active site 
nucleophiles (Kisselev and Goldberg, 2001). Thus, together with their bacterial 
homologue Hs1VU complex, they form a new class of proteolytic enzymes known as 
threonine proteases (Kisselev and Goldberg, 2001).  
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1.2.3.1 Proteasome inhibitors 
The study of the roles of the ubiquitin proteasome system has been greatly aided by 
the identification of several classes of proteasome inhibitors. Although the 
proteasome has multiple active sites, inhibition or inactivation of the chymotrypsin-
like site alone is sufficient to cause a large decrease in the rates of protein degradation 
(reviewed by Kisselev and Goldberg, 2001). 
 
One class of the most commonly used proteasome inhibitors is the peptide aldehydes, 
which include MG132 (Cbz-LLL-H) (Fig 1.3A), MG115 and ALLN. These are 
reversible inhibitors which are substrate analogues and transition-state inhibitors of 
the chymotrypsin-like active sites of the proteasome although they are also able to 
inhibit calpains and lysosomal cathepsins (reviewed by Lee and Goldberg, 1998). 
MG132 is the most potent and selective of the commercially available aldehydes, 
requiring at least 10-fold higher concentrations before they inhibit calpains and 
cathepsins (reviewed by Fenteany et al., 1995). Thus due to its low cost, rapid 
reversibility of action and relative selectivity, MG132 was used as one of the 
proteasome inhibitors in this study.  
 
The other proteasome inhibitor used in this study was the structurally distinct 
lactacystin (Fig 1.3B). This is a Streptomyces metabolite and is a much more specific 
and expensive proteasome inhibitor. It acts irreversibly on the trypsin-like and 
chymotrypsin-like active sites and reversibly on the peptidylglutamyl-peptide active 
sites, functioning as a pseudosubstrate that becomes covalently linked to the hydroxyl 
groups on the active site threonine of the β subunits (Geier et al., 1999). The two 
serine proteases known to be inhibited by lactacystin are cathepsin A (Dick et al., 
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1997) and tripeptidyl peptidase II (Dick et al., 1996), making lactacystin a far more 
selective proteasome inhibitor compared to the peptide aldehydes. In aqueous solution, 
lactacystin undergoes a spontaneous transition to its β-lactone derivative, clasto-
lactacystin β-lactone (Fig 1.3C), which can cross the plasma membranes of 
mammalian cells (Lee and Goldberg, 1998) and is the active form of the inhibitor 




Fig 1.3 Structure of various proteasome inhibitors.  
 
A. MG132; B. lactacystin; C. clasto-lactacystin β-lactone; D. epoxomicin (from 
Calbiochem Datasheets 474790, 426100, 426102, 324800). 
 
 
Currently the most selective proteasome inhibitor known is the α′, β′-epoxyketone 
containing natural product epoxomicin (Fig 1.3D) which has not been found to inhibit 
any other proteolytic enzyme tested (Kisselev and Goldberg, 2001). This is a natural 
product isolated from an Actinomycetes strain when it was found to have anti-tumour 




epoxomicin arises by its formation of a cyclical morpholino ring with the proteasome 
(Kisselev and Goldberg, 2001). This adduct formation requires both a free N-terminal 
amino group and a side chain nucleophile and therefore cannot be formed with a 
cysteine or serine protease as these enzymes do not have a free N-terminus adjacent to 
the nucleophile group (Kisselev and Goldberg, 2001).  
 
1.3 Relationship between neurodegenerative diseases and the UPS 
As previously discussed, the close relationship between neurodegeneration and the 
UPS has been implicated through consistent findings of ubiquitin-positive protein 
aggregates in various neurodegenerative disorders, including AD, PD, ALS and HD. 
Thus the inhibition of the UPS is hypothesized to play a key role in mediating cellular 
toxicity in such neurodegenerative diseases (Kitada et al., 1998; McNaught et al., 
2003; McNaught et al., 2002; McNaught and Jenner, 2001; Polymeropoulos et al., 
1997). This section discusses in more detail the involvement of the UPS in PD and 
AD pathogenesis. 
 
1.3.1 UPS dysfunction in PD 
Most PD cases are sporadic with poorly understood etiology. On the other hand, while 
familial PD with specific genetic defects accounts for less than 10% of PD cases, the 
identification and functional characterization of those genes have led to a clearer 
understanding of the possible molecular mechanisms of nigral neuronal degeneration 
in PD. These PD-causing mutations have been found in  α-synuclein (Kruger et al., 
1998; Polymeropoulos et al., 1997), ubiquitin carboxy-terminal hydrolase L1 
(UCHL1) (Leroy et al., 1998), parkin (Kitada et al., 1998) and DJ-1 (Bonifati et al., 
2003). The implicated pathogenic mechanisms for all the above genes have been 
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found to be associated directly or indirectly with dysfunctions of the UPS and are 
discussed in greater detail below. 
 
1.3.1.1 Parkin 
Parkin is an E3 ubiquitin ligase whose levels and enzymatic activity are significantly 
decreased or absent in both degenerating and unaffected brain regions in about 50% 
of patients with autosomal recessive juvenile parkinsonism (ARJP), one of the most 
common familial forms of PD (Shimura et al., 2000; Shimura et al., 1999). This 
suggests that substrates normally ubiquitinated by parkin for subsequent proteasomal 
degradation would accumulate as a result of mutations in parkin. Hence it is of 
interest to identify the native cellular substrates of parkin, the hypothesis being that 
the accumulation of one of several of these proteins could be involved in the 
pathogenesis of ARJP. The substrates identified to be ubiquitinated by parkin include 
the cell-division-control-related protein 1 (CDCrel-1) (Zhang et al., 2000), a 
glycosylated isoform of α-synuclein (Shimura et al., 2001), synphilin-1 (Chung et al., 
2001), the Parkin-associated endothelial-like (Pael) receptor (Imai et al., 2001) and 
cyclin E (Staropoli et al., 2003). Both the glycosylated isoform of α-synuclein and 
Pael receptor which is a putative G protein-coupled transmembrane polypeptide, have 
been found to accumulate without ubiquitination in the substantia nigra of patients 
with ARJP (Imai et al., 2001; Shimura et al., 2001).   
 
The synaptic vesicle-associated protein CDCrel-1 was the first parkin substrate to be 
identified (Zhang et al., 2000). While this protein has been suggested to be involved 
in regulating synaptic vesicle release in the nervous system, CDCrel-1 null mice 
demonstrated that it is dispensable in neuronal development and function (Peng et al., 
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2002). It is possible that the accumulation of this substrate due to the absence of 
parkin-mediated degradation could result in neuronal dysfunction and increased levels 
of CDCrel-1 may also disrupt dopamine release, leading to PD. Such speculation 
however remains to be further verified. 
 
On the other hand, the accumulation of degradation-resistant α-synuclein is clearly 
linked to PD pathogenesis as described in Section 1.3.1.3. The synaptic vesicle 
enriched protein synphilin-1 interacts with both parkin and α-synuclein (Chung et al., 
2001) and has been shown to be one of the components in Lewy bodies (Wakabayashi 
et al., 2000). Co-expression of synphilin-1, α-synuclein and parkin in cultured cells 
resulted in the formation of ubiquitin-positive Lewy body-like aggregates while in the 
presence of mutated parkin, ubiquitination of the aggregates was disrupted (Chung et 
al., 2001). These results suggest a molecular link between the UPS, Lewy body 
formation, parkin, α-synuclein and synphilin-1 (Lim and Lim, 2003).  
 
Another parkin substrate is cyclin E, a cell cycle regulatory protein which has been 
shown to trigger apoptosis when accumulated in post-mitotic neurons (Staropoli et al., 
2003). Overexpression of parkin has a neuroprotective effect against cyclin E 
accumulation, indicating the critical role parkin plays in maintaining cyclin E levels in 
neurons (Staropoli et al., 2003). 
 
The Pael receptor is another substrate of Parkin. It has been found to become 
misfolded and ubiquitinated when overexpressed, causing cell death via the unfolded 
protein response (UPR) (Imai et al., 2001). The co-expression of parkin, however, is 
able to rescue the cells from this Pael receptor-induced cell toxicity (Imai et al., 2001). 
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Thus parkin may play an important role in the suppression of cellular unfolded protein 
stress by its clearance of improperly folded proteins in the endoplasmic reticulum. 
Mutations in parkin could thus result in the accumulation of misfolded substrate 
proteins, leading to cell death.  
 
Taken together, it can be seen that the pathogenic effect of mutations in parkin could 
arise by preventing the normal ubiquitination and proteasomal degradation of 
substrate proteins, leading to a build up of misfolded or toxic proteins, thus disrupting 
normal cellular functions. 
 
1.3.1.2 Ubiquitin carboxy-terminal hydrolase L1 (UCHL1) 
UCHL1 is a deubiquitinating enzyme responsible for degrading polyubiquitin chains 
back to their ubiquitin monomers (Solano et al., 2000). A point mutation (I93M) 
which impairs its activity was identified in a small German family with PD (Leroy et 
al., 1998). This gene mutation is responsible for only a few rare cases of PD as similar 
mutations were not found in hundreds of other patients with familial and sporadic PD 
(Wintermeyer et al., 2000). Loss of UCHL1 activity in PD might lead to reduced 
ubiquitination, impaired protein clearance, dysfunction in the proteolytic pathway, 
protein aggregation including that of the UCHL1 protein itself (which is indeed 
present in Lewy bodies), and consequent neurodegeneration (McNaught and Olanow, 
2003). 
 
It has also been reported that while the monomeric form of UCHL1 has 
deubiquitinating activity, its dimers have a ubiquitin ligase activity that increases 
polyubiquitination of mono- or diubiquitinated α−synuclein  suggesting that it acts as 
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an E4 (Liu et al., 2002). This ubiquitin ligase activity is decreased by the pathogenic 
I93M mutation,  indicating that the ligase activity as well as the hydrolase activity of 
UCHL1 may play a role in proteasomal protein degradation (Liu et al., 2002). While 
further studies are still needed to understand how UCHL1 mutations result in 
dopaminergic cell death, these findings are consistent with the hypothesis that PD 
pathogenesis involves the dysfunction of the UPS.  
 
1.3.1.3 α−Synuclein 
Another important protein that links UPS dysfunction to the pathogenesis of PD is α-
synuclein. This is a small, 140 amino acid residue protein, the wild-type of which is 
abundant in the brain and highly expressed in presynaptic nerve terminals (reviewed 
by Lim and Lim, 2003). While its exact function is not fully understood, it appears to 
play a role in synaptic maintenance as well as the modulation of dopaminergic 
neurotransmission (reviewed by Lim and Lim, 2003). Two independent missense 
mutations, A53T (Polymeropoulos et al., 1997) and A30P (Kruger et al., 1998), are 
responsible for rare cases of autosomal dominant familial PD. Neurodegeneration 
mediated  by  α-synuclein has been found to be associated with the abnormal 
aggregation of detergent-insoluble α-synuclein (reviewed by Lim and Lim, 2003). 
Mutated α-synuclein has a greater tendency to aggregate and fibrillize into structures 
resistant to protein degradation, thus leading to proteasomal impairment  as well as 
the formation of insoluble protein aggregates (McNaught and Olanow, 2003). The 
A30P mutant α-synuclein has been found to inhibit the peptidylglutamyl-peptide 
hydrolytic activity of the proteasome by 25% and the trypsin-like and chymotrypsin-
like activities by slightly smaller amounts while wild-type α-synuclein had a much 
smaller effect (Tanaka et al., 2001). The A53T mutant α-synuclein was also shown to 
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inhibit the chymotrypsin-like activity of the proteasome (Stefanis et al., 2001). α-
synuclein has also been found to interact with the regulatory 19S cap of the 
proteasome (Ghee et al., 2000), which may also result in proteasome inhibition. 
Studies have also shown that the protofibrils of mutant α-synuclein in particular, are 
able to permeabilize synaptic vesicles resulting in the leakage of vesicular dopamine 
in dopaminergic cells (Volles and Lansbury, 2002). This would result in intracellular 
oxidative stress and subsequent proteasomal dysfunction as well. Moreover, wild-type 
α-synuclein has been shown to be a major component of Lewy bodies, suggesting that 
it may also be involved in sporadic PD (Spillantini et al., 1997). Finally, an O-
glycosylated form of α-synuclein from human brain was found to be ubiquitinated by 
parkin (Shimura et al., 2001), suggesting that loss of parkin function might result in 
the accumulation of α-synuclein. It is also of interest that the overexpression of parkin 
has been found to rescue cultured catecholaminergic neurons from the toxic effects of 
α-synuclein, indicating that the two proteins are involved in a common pathway  




Recent studies have shown that mutations in the DJ-1 gene are associated with ARJP 
(Bonifati et al., 2003). Although the exact function of this protein is still unclear, it 
may be involved as an antioxidant in protecting other proteins from damage by 
oxidative stress (Bonifati et al., 2003). A point mutation in DJ-1, L166P, which is 
associated with ARJP, has been found to cause its rapid degradation by the UPS 
(Miller et al., 2003). Thus the UPS may contribute to PD pathogenesis by its removal 
of a mutated but active DJ-1 protein.  
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1.3.1.5 Sporadic PD 
In the case of sporadic PD, decreases in proteosomal function have been found in the 
brains of postmortem patients, with the most severe inhibition of the proteasome in 
the substantia nigra, the brain region that demonstrates the greatest degree of 
pathology (McNaught et al., 2003; McNaught and Jenner, 2001). The presence of 
increased levels of oxidatively damaged proteins (Alam et al., 1997) and increased 
protein aggregation (Lopiano et al., 2000) in the substantia nigra of patients with 
sporadic PD lend further support to the hypothesis that impaired protein clearance by 
the UPS is a critical factor in the pathogenesis of PD.  
 
Neuronal death in the substantia nigra of sporadic PD patients has also been 
associated with reduced activity of complex I of the mitochondrial respiratory chain 
(Schapira et al., 1989; Schapira et al., 1990) and oxidative stress, reflected in 
increased levels of oxidative damage to DNA, proteins and lipids in postmortem 
central nervous system (CNS) tissues from PD patients (reviewed by Tsang and 
Soong, 2003), depletion of reduced glutathione content (Sian et al., 1994) and 
increased iron levels (Dexter et al., 1991). Interestingly, the two biochemical deficits 
of decreased mitochondrial complex I activity and reduced proteasomal activity have 
been found to be inter-related. Complex I inhibition was shown to decrease 
proteasomal activity in primary mesencephalic cultures while conversely, impaired 
proteasome function increased neuronal vulnerability to normally subtoxic levels of 
reactive oxygen species (ROS) (Hoglinger et al., 2003). Studies have found that the 
inhibition of complex I led to aggregation and accumulation of α-synuclein (Betarbet 
et al., 2000; Kowall et al., 2000) and other forms of oxidative stress also promote α-
synuclein aggregation (reviewed by Ischiropoulos and Beckman, 2003). Oxidative 
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stress and UPS disruption are also interconnected, with the blockage of the 
proteasome due to oxidative damage and substrate overloading possibly leading to 
further oxidative stress, which would cause more cellular damage, exacerbating 
proteasome impairment (Halliwell, 2002). 
 
Thus evidence gathered from both familial and sporadic PD points towards the 
dysfunction of the UPS playing a pivotal role in PD pathogenesis.  
 
1.3.2 UPS dysfunction in AD 
As mentioned in Section 1.1.1, while Aβ and tau have long been thought to play a 
primary role in the pathogenesis of AD, evidence has accumulated for the UPS 
playing a key role as well. Although there have been no reports of mutations in 
enzymes of the UPS in familial AD up to now, evidence indicating that impairment of 
the UPS could be involved in the pathogenesis of AD comes from postmortem tissue 
studies which show a region-specific decrease in proteasome activity in AD patients 
(Keck et al., 2003). Brain regions like the hippocampus and related limbic structures 
and inferior parietal lobe, which are particularly affected in AD showed the greatest 
decrease in proteasomal activity while activity was normal in the occipital lobe and 
cerebellum which are relatively unaffected in AD (Keller et al., 2000). In addition, 
there is evidence showing reduced activities of E1 and E2 enzymes in cerebral cortex 
samples from AD patients when compared to age-matched controls (Lopez Salon et 




Other evidence comes from a frameshift mutant form of ubiquitin, ubiquitin-B+1 
(UBB+1), which is expressed and accumulates in the neurons of AD patients (van 
Leeuwen et al., 1998). UBB+1 has also been found to arise in the ageing brain and is a 
result of ‘molecular misreading’, where two nucleotides in the mRNA coding for 
ubiquitin are deleted during or after transcription into mRNAs derived from a non-
mutated ubiquitin gene that contains specific sequence repeats (van Leeuwen et al., 
2000). While this mutant ubiquitin can be ubiquitinated, it cannot be covalently 
attached to other proteins (De Vrij et al., 2001). Studies have also shown that UBB+1 
behaves as a ubiquitin-fusion-degradation substrate and therefore a target for the 
proteasome. However, it is also a potent and specific inhibitor of ubiquitin-dependent 
proteolysis in neuronal cells (Lam et al., 2000; Lindsten et al., 2002)  and a 
component of neurofibrillary tangles (van Leeuwen et al., 1998). As increased levels 
of UBB+1 have also been found in other neurodegenerative disorders e.g. tauopathy 
progressive supranuclear palsy (Fischer et al., 2003), it is unlikely to be a direct cause 
of AD. However it may contribute to the pathogenesis of AD.  
 
Further evidence for the dysfunction of the UPS being involved in AD comes from 
studies of E2-25K/Hip-2, an unusual E2-ubiquitin conjugating enzyme found to be 
upregulated in AD brain as well as in neuronal cultures exposed to Aβ1-42 (Song et al., 
2003). This pro-apoptotic protein was found to mediate Aβ and UBB+1 neurotoxicity 
by inhibiting the proteasome (Song et al., 2003) and could therefore play a role in the 
pathogenesis of AD. 
 
Proteasome inhibition has also been shown to be linked to Aβ production. PS1 and 2 
are both actively degraded by the proteasome in normal conditions (Fraser et al., 1998; 
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Kim et al., 1997), as is Pen-2, another member of the γ-secretase complex (Bergman 
et al., 2004). Thus the dysfunction of the proteasome would lead to increased levels of 
these proteins, resulting in enhanced γ-secretase activity and hence more Aβ 
production. The C-terminal part of APP has also been found to be processed by the 
20S proteasome (Nunan et al., 2003). Taken together, these results indicate that an 
AD-associated dysfunction of the UPS would lead to increased γ-secretase APP 
processing, resulting in elevated Aβ levels.  
 
Another feature of AD is increased levels of oxidative stress in affected brain regions. 
For example, the unsaturated aldehyde 4-hydroxynonenal (4-HNE), malondialdehyde 
(MDA), F2- and F4-isoprostanes, all markers for lipid peroxidation have been found in 
the cortex and hippocampus of AD patients (reviewed by Andersen, 2004; Halliwell, 
2001) while increased levels of nitrated proteins, a marker of damage by reactive 
nitrogen species (RNS), have also been observed in specific brain regions of patients 
with AD (reviewed by Halliwell, 2002). Furthermore, the antioxidant enzymes 
superoxide dismutase (SOD), catalase, glutathione peroxidase and glutathione 
reductase that would normally protect against oxidative stress have been found to 
display reduced activities (reviewed by Andersen, 2004). While the exact cause for 
oxidative stress in AD brain remains uncertain, Aβ is likely to contribute through the 
generation of free radicals (Miranda et al., 2000). Increased oxidative stress and the 
aggregation of abnormal proteins are inter-related. While mildly oxidized proteins are 
easily degraded by the UPS, studies have shown that severe oxidation results in 
aggregated, cross-linked and insoluble proteins that are resistant to proteasome 
degradation (reviewed by Grune et al., 2003). Also, oxidative stress could lead to the 
direct inactivation of the proteasome, as reactive oxygen and nitrogen species, 
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including HNE, have been found to directly damage the proteasome (reviewed by 
Halliwell, 2002). The dysfunction of the proteasome would then cause the 
accumulation of abnormal and oxidized protein.  
 
Thus it can be seen that there is strong evidence supporting the premise that the 
dysfunction of the UPS plays a central role in AD pathology. 
 
1.4 Induction of apoptosis by proteasome inhibition 
Apoptosis is a type of cell death mediated by caspases, a family of cysteine proteases 
with aspartate specificity. These proteases are expressed constitutively as inactive 
zymogens (procaspases) and are activated upon specific proteolytic cleavage in a 
sequential cascade or by autocatalysis (Thornberry and Lazebnik, 1998). Once 
activated, various cellular substrates are cleaved, resulting in the characteristic 
biochemical and morphological phenotypes of apoptosis- including DNA 
fragmentation, chromatin condensation, membrane blebbing, cell shrinkage, and 
disassembly into membrane-enclosed vesicles (apoptotic bodies). These apoptotic 
bodies are then phagocytosed in vivo without the release of intracellular contents 
(reviewed by Zimmermann et al., 2001).  
 
There are at least two pathways leading to the activation of apoptosis: the 
mitochondrial (intrinsic) pathway and the death receptor (extrinsic) pathway. The 
extrinsic pathway involves the binding of death ligands to death receptors on the 
plasma membrane (e.g. Fas/CD95/Apo-1). This results in the recruitment of the 
adaptor molecule Fas associated death domain protein (FADD), which possesses 
death effector domains (DED) that can interact with the DED of procaspase 8, 
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enabling their proteolytic autoactivation (Ashkenazi and Dixit, 1998). Downstream of 
caspase 8, two different pathways lead to apoptosis. In Type I cells, other caspases 
(e.g. caspase 3) are activated directly while in Type II cells, the pro-apoptotic protein 
Bid is cleaved and activated by caspase 8, followed by its translocation to the 
mitochondria with the resulting permeabilization of the outer mitochondrial 
membrane (Scaffidi et al., 1999). Thus the extrinsic pathway converges with the 
intrinsic pathway at the mitochondria in the case of the Type II cells.  
 
The intrinsic pathway involves the mitochondria playing a key role, where in response 
to various stimuli, it releases cytochrome c from its intermembrane space after the 
permeabilization of its outer membrane (Green and Reed, 1998). Cytosolic 
cytochrome c then binds to apoptosis proteases-activating factor-1 (Apaf-1), 
triggering the ATP-dependent oligomerization of Apaf-1, while exposing its caspase 
recruitment domain (CARD) (Hu et al., 1999; Li et al., 1997). Procaspase 9 is then 
recruited by interaction with the CARD domain, forming the apoptosome, the caspase 
9 activation complex. Active caspase 9 then amplifies the caspase cascade by 
triggering the proteolytic maturation of procaspase 3 (Li et al., 1997). Upon activation, 
caspases then cleave various target proteins, causing the breakdown of structural 
components of the cell as well as disabling important cellular processes with the 
eventual result of cell death. 
 
Studies on rat primary cortical neurons have shown that proteasome inhibition results 
in apoptotic cell death, with the disruption of mitochondrial membrane potential, 
release of cytochrome c from the mitochondria into the cytosol and the activation of 
caspase 3 (Qiu et al., 2000). Upon the inhibition of caspase 3 as well as the 
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overexpression of the anti-apoptotic protein Bcl-xL, lactacystin-induced neuronal 
apoptosis was blocked (Qiu et al., 2000). These findings have been confirmed by 
other studies, which also showed that proteasome inhibitor-mediated neuronal 
apoptosis is dependent upon transcription (Rideout and Stefanis, 2002).  
 
1.5 Induction of heat shock response by proteasome inhibition 
The inhibition of the proteasome on the other hand, has also been shown to trigger a 
heat shock response, leading to the expression of heat shock proteins (HSPs) and 
stress proteins of the endoplasmic reticulum (Bush et al., 1997). This induction is 
likely to be due to the accumulation of abnormal and misfolded proteins as a result of 
decreased protein degradation caused by proteasome inhibition. This heat shock 
response, which is a result of increased gene transcription, has been found to increase 
cell tolerance to stressful conditions and occurs rapidly- within 2 h of proteasome 
inhibition (Bush et al., 1997). The increased expression of HSPs might play protective 
roles to prevent protein aggregation and misfolding after stress (Mathew and 
Morimoto, 1998) or they may also suppress apoptotic signaling during stress 
(Parcellier et al., 2003). Thus pro-apoptotic stimuli can result in protective responses 









1.6 Aims of this study 
Since proteasome inhibition is likely to play a contributing role to neurodegeneration 
and is also able to generate initial neuroprotective proteins such as HSPs, a microarray 
analysis was carried out to identify differentially expressed genes induced by 
proteasome inhibitors in a primary neuronal culture model so as to have a clearer idea 
of the possible pro-apoptotic and anti-apoptotic pathways activated in this process. 
 
Previous microarray analyses have been done to study the global cellular response of 
various cell types to proteasome inhibition. These include Saccharomyces cerevisiae 
(Fleming et al., 2002), human breast carcinoma cells (Zimmermann et al., 2000), as 
well SH-SY5Y neural cell lines (Ding et al., 2004).  However, a similar analysis on 
the effects of proteasomal inhibition upon primary neuronal cells has so far not been 
reported.  
 
Thus the aims of this study were: 
1. To identify and validate differentially expressed genes in lactacystin-induced 
apoptosis in murine primary cortical neurons and 
2. To investigate the roles of heat shock protein 22 (HSP22), annexin A3 (Anxa3) 













MATERIALS AND METHODS 
28 
2. Materials and methods 
2.1 Murine primary cortical neurons 
Cultures of mouse embryonic day 15-16 cortical neurons were prepared as described 
previously (Cheung et al., 2004; Cheung et al., 1998). In brief, cortices were 
microdissected aseptically from the brains of mouse foetuses and subjected to trypsin 
digestion followed by mechanical trituration. The dissociated cells were collected by 
centrifugation and resuspended in Neurobasal (NB) medium (Gibco, Carlsbad, 
CA) containing 2.5% B-27 (Gibco) and 0.25% GlutaMAX-I (Gibco) 
supplements, 10% fetal calf serum (Sigma, St. Louis, MO) and 1% penicillin-
streptomycin (Sigma). The cells were seeded into poly-D-lysine-coated 6- and 24- 
well plates (Nalge Nunc International, Rochester, NY) at a density of 2 x 105 cells per 
cm2 and maintained at 37oC under 5% CO2. After 24 h in vitro, the culture medium 
was changed to serum-free NB medium with 2.5% B-27 supplement, 0.25% 
GlutaMAX-I supplement and 1% penicillin-streptomycin.  
 
2.2 Cell lines 
2.2.1 Maintenance and culture of cell lines 
 
The mouse neuroblastoma Neuro2a (American Type Culture Collection) and human 
neuroblastoma SH-SY5Y (American Type Culture Collection) cell lines were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco) containing 100 
U/ml penicillin, 100 µg/ml streptomycin, and 10% fetal bovine serum (Hyclone 
Laboratories, Logan, UT). The rat pheochromocytoma-derived PC12 cell line 
(American Type Culture Collection) was maintained in the same medium but with an 
additional 5% horse serum (Sigma). Subculture of cells was carried out when 
confluence was reached. For Neuro2A and SH-SY5Y cells, this was done by 
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removing medium from the flasks and rinsing the adherent cells with Dulbecco’s 
phosphate-buffered saline (PBS) (Gibco) twice. Sterile 0.05% trypsin-EDTA 
(Sigma) was then added (1 ml/25 cm2) and the flasks were incubated at 37oC for 10 to 
15 min until the cells detached. DMEM medium was then added and the cells were 
dispersed by pipetting up and down repeatedly. In the case of the less adherent PC12 
cells, the medium was removed during subculture, followed by rinsing of the attached 
cells with new DMEM medium with repeated pipetting to further disperse the cells. 
The cells were then seeded at suitable concentration in growth medium and 
maintained in a humidified 5% CO2 incubator at 37oC. Both Neuro2a and SH-SY5Y 
cells were seeded at a density of 1.1 x 105 cells/ml while PC12 cells were seeded at a 
density of 3.3 x 105 cells/ml overnight before treatment or transfection.  
 
2.2.2 Differentiation of cell lines 
Differentiation of Neuro2a and SH-SY5Y cells was carried out by changing the 
medium of the cells seeded onto 6- or 24-well plates to a differentiating medium 
consisting of DMEM, 2% fetal bovine serum and 20 µM retinoic acid (Sigma). PC12 
cells were differentiated similarly except that the differentiating medium was made up 
of DMEM, 1% fetal bovine serum, 0.5% horse serum (Sigma) and 100 ng/ml nerve 
growth factor (Calbiochem, Darmstadt, Germany). 
 
2.3 Drug treatments 
Cortical neurons at day 5 in vitro were treated with 0.1-2.0 µM lactacystin 
(Calbiochem), a specific inhibitor of the proteasome for 24 or 48 h. Other agents used 
are as follows: 0.25-0.5 µM staurosporine (Sigma), 1-5 µM colchicine (Sigma), 0.1-
2.0 µM MG132 (Calbiochem), 75-500 µM hydrogen peroxide, and 20-50 µM 
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amyloid beta 1-40 (Aβ1-40) (Bachem AG, Hauptstrasse, Bubendorf). Cell lines were 
treated 24 h after seeding onto 6- or 24-well plates. 
 
2.4 Assessments of cell viability  
The 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction 
assay was used to assess cell viability by measuring the conversion of the yellow 
tetrazolium salt to the colored formazan product in viable cells. Treated cells in 24-
well plates were incubated in a final MTT (Duchefa, Haarlem, The Netherlands) 
concentration of 0.5 mg/ml at 37oC for 30 min. The culture medium was then 
removed and the formazan product of each well was dissolved in 200 µl dimethyl 
sulfoxide (DMSO) (Merck, Whitehouse Station, NJ). The absorbance of the solution 
was read at 570 nm using a Tecan plate reader (Tecan, Grödig/Salzburg, Austria). 
 
2.5 Transfection of murine primary cortical neurons with plasmid DNA 
Transfection of murine primary cortical neurons was performed using 
Lipofectamine  2000 (Invitrogen, Carlsbad, CA). The cells were seeded at a density 
of 2x105 cells/cm2 into 6-well plates as described in Section 2.1. The culture medium 
was then changed to NB medium containing 2.0% B-27 supplements only (2 ml/well). 
2 µg plasmid DNA was mixed with 250 µl Opti-MEM (Gibco) serum-free medium 
for each well of a 6-well plate while 4 µl of Lipofectamine  2000 cationic lipid 
reagent was mixed with 250 µl of Opti-MEM in a separate tube. The diluted lipid 
reagent was then added dropwise to the diluted plasmid DNA, mixed by pipetting and 
incubated for 20 min at room temperature for the formation of complexes. After 
incubation, 500 µl of the complex solution was added to each well, mixed gently by 
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swirling the plate and incubated for 3 h, 37oC, after which the medium was changed 
to NB medium containing 2.0% B-27 supplements. 
 
2.6 Transfection of murine primary cortical neurons with siRNA  
The TransIT-TKO® Transfection Reagent (Mirus, Madison, WI) was used for siRNA 
transfection in murine primary cortical neurons. The medium was changed to NB 
medium containing 2.0% B-27 supplements (1.5 ml/well). 2 µl of TransIT-TKO® was 
mixed with 400 µl of Opti-MEM, vortexed and incubated for 10 min at room 
temperature. After this, siRNA (Dharmacon, Lafayette, CO) was mixed to a final 
concentration of 10 nM per well into the diluted TransIT-TKO®  reagent, followed by 
a 10 min incubation at room temperature. 400 µl of this TransIT-TKO® reagent-
siRNA complex mixture was then added to each well dropwise with swirling, 
followed by a 24 h incubation at 37oC. The expression of the silenced gene was then 
evaluated using Western blot analysis (Section 2.13). 
 
2.7 Transfection of cell lines 
Transfection of naïve Neuro2A, SH-SY5Y and PC12 cells was performed using 
TransFectin Reagent (Bio-rad Laboratories, Hercules, CA). The cells were seeded 
as described in Section 2.2.1 such that they were about 50% confluent after 24 h of 
seeding. The culture medium was then changed to serum-containing DMEM (Section 
2.2.1) but without any antibiotics. 500 µl of medium was added per well in a 24-well 
plate and 2 ml per well for 6-well plates. 1 µg plasmid DNA was mixed with 50 µl 
DMEM for each well of a 24-well plate while 4 µg plasmid DNA was mixed with 250 
µl DMEM for each well of a 6-well plate. 1 µl of TransFectin lipid reagent was 
mixed with 50 µl of DMEM for each well of a 24-well plate while 4 µl was mixed 
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with 250 µl DMEM for a well of a 6-well plate. The latter step was carried out in a 
polystyrene tube. The diluted plasmid DNA was then added to the diluted 
TransFectin lipid reagent, mixed by pipetting and incubated for 20 min at room 
temperature for the formation of DNA-TransFectin lipid reagent complexes. After 
incubation, 100 µl (24-well plate) or 500 µl (6-well plate) of the DNA-TransFectin 
lipid reagent complexes were added to each well and mixed gently by swirling the 
plate. PC12 and SH-SY5Y cells were then incubated with the transfection reagent for 
3 h, 37oC, after which the medium was changed to complete DMEM medium with 
serum. Neuro2a cells were incubated with the transfection reagent overnight at 37oC 
without significant loss of cell viability.  
 
2.8 Isolation of total RNA 
2.8.1 RNeasy Mini Kit 
RNeasy Mini Kit (Qiagen, Valencia, CA) was used to extract total RNA for use in the 
microarray analysis. Cells in 6-well plates were harvested after complete aspiration of 
cell culture medium, followed by the addition of 350 µl of buffer RLT*, a strong 
denaturing guanidine isothiocyanate-containing buffer. This buffer disrupts and lyses 
the sample, as well as inactivates RNases to prevent the breakdown of RNA. The 
lysate was then homogenized by passing 10 times through a 21½ gauge needle fitted 
to an RNase-free syringe. 1 volume of 70% ethanol was then added to the 
homogenized lysate so as to obtain appropriate binding conditions and the sample was 
then applied to an RNeasy mini column which contains a silica-gel-based membrane 
to adsorb total RNA. Wash buffers RW1*, and RPE*, were then applied to wash 
away contaminants such as salts, proteins and other cellular impurities. Total RNA 
                                                
* Exact composition of buffer is not provided by the manufacturer. 
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was then eluted with 30 µl of diethylpyrocarbonate (DEPC)-treated water. DEPC-
treated water was prepared by dissolving DEPC (Sigma) in distilled water to a final 
concentration of 0.1%. The solution was then left to stand overnight at room 
temperature and autoclaved the next day for 30 min.  
 
2.8.2 High Pure RNA Isolation Kit 
The High Pure RNA Isolation Kit (Roche, Mannheim, Germany) was used to extract 
total RNA for use in real-time RT-PCR applications. While the principle behind this 
kit and that of Qiagen’s RNeasy Mini Kit is the same, the High Pure RNA Isolation 
Kit has the advantage of an additional on-column DNase 1 digestion step. This is a 
necessary step for real-time RT-PCR applications as the technique is sensitive even to 
very low amounts of genomic DNA contamination.  
 
The procedure for the High Pure RNA Isolation Kit was as follows: After the 
complete removal of culture media, 800 µl of lysis/-binding buffer (4.5 M guanidine 
hydrochloride, 50 mM Tris-HCl and 30% Triton X-100, pH 6.6) was added to lyse the 
cells and inactivate RNases simultaneously. The cell lysate was then collected and 
homogenized in the same manner as described for the RNeasy Mini Kit, following 
which it was transferred to a High Pure filter tube. This tube contains glass fibers 
which bind nucleic acids specifically in the presence of chaotropic salts. The 
conditions in the tube are optimal for RNA binding and any contaminating DNA 
would be digested by the addition of DNase I (182 U) into the column. After washing 
with wash buffers I (5 M guanidine hydrochloride and 20 mM Tris-HCl, pH 6.6) and 
II (20 mM NaCl and 2 mM Tris-HCl, pH 7.5), total RNA was eluted with the elution 
buffer (nuclease-free, sterile bidest. H2O) provided in the kit and stored at –80oC. 
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2.9 Determination of quantity and quality of total RNA 
The concentration of RNA was determined by measuring the absorbance at 260 nm 
(A260) in a spectrophotometer (Beckman DU-64, Fullerton, CA). When diluted in 
water, an A260 of 1 unit is equivalent to 40 µg of RNA per ml. 
 
The quality of extracted RNA was estimated by its A260/A280 ratios. Pure RNA is 
expected to have an A260/A280 ratio of 2 (Sambrook et al., 1989). The integrity of total 
RNA extracted was also checked using denaturing gel electrophoresis as described in 
Section 2.10. The 28S ribosomal RNA bands should have approximately twice the 
intensity of the 18S RNA bands. 
 
2.10 Denaturing gel electrophoresis 
1% (w/v) agarose gel was prepared by boiling 1.0 g of agarose in 87 ml of DEPC-
treated water. After the gel was cooled to about 60oC, 10 ml of 10x 3-(N-morpholino) 
propanesulfonic acid (MOPS) buffer (10x concentrate composed of 200 mM MOPS, 
50 mM sodium acetate, 20 mM EDTA) and 3 ml of 37% formaldehyde was added. 
The gel was then cast in a fume hood and immersed in 1x MOPS running buffer when 
set. RNA samples were loaded together with RNA sample loading buffer without 
ethidium bromide (Sigma) in a ratio of 2:1. The samples were heated to 65oC for 10 
min before loading and then chilled on ice. The samples were run in at 100 V and then 
at a constant voltage of 5 V/cm across the two electrodes until the loading dye 
migrated to approximately two-thirds of the gel.  
 
To visualize the RNA bands, the gel was soaked in a 0.5 µg/ml ethidium bromide 
(Bio-Rad Laboratories) solution for 15 min with gentle shaking, followed by two 
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rinses with DEPC-treated water for 15 min. The gel was then viewed using a UV-
transilluminator (ChemiGenius2 Bio Imaging System, SynGene, Cambridge, UK). 
 
2.11 Microarray analyses 
Microarray analysis was carried out using 13 murine Affymetrix U74A microarrays 
(Affymetrix, Santa Clara, CA) according to the Affymetrix expression analysis 
technical manual. In addition, 13 GeneChip Test3 arrays (Affymetrix) were also used 
to check the quality of the targets and the labeling efficiency before analysis on the 
actual U74A microarrays. Each Test3 array contains probe sets representing a subset 
of characterized genes from various organisms as well as a subset of human and 
mouse housekeeping genes.  
 
The following controls/treatments were used: control (n=4), 24 h 0.5 µM lactacystin 
treatment (n=3), 24 h 1 µM lactacystin treatment (n=3) and 48 h 1 µM lactacystin 
treatment (n=3). These treatment conditions were chosen as previous observations 
have shown that at 24 h 1 µM lactacystin treatment, cell viability and proteasome 
activity is reduced to about 50 – 60% that of control (Fig 3.1; Cheung et al., 2004).   
 
Total RNA was extracted from pooled control and treated samples using RNeasy kit 
(Qiagen) (Section 2.8.1) and RNA quality was assessed by spectrophotometric 
analysis (Section 2.9) as well as electrophoresis on a denaturing 1% agarose gel 





2.11.1 Synthesis and clean-up of cDNA from total RNA 
All reagents used for the synthesis of complementary DNA (cDNA) were from 
Invitrogen. Double-stranded cDNA was synthesized from 7 µg of total RNA using 2 
µl of oligo dT primer containing the T7 promoter as follows. The mixture was 
incubated at 70oC using a thermocycler (PTC-100TM Peltier Thermal Cycler, MJ 
Research) for 10 min, then placed on ice after a brief spin for primer hybridization. 
Next, 4 µl of first strand cDNA buffer (250 mM Tris-HCl, pH8.3, 375 mM KCl and 
15 mM MgCl2), 2 µl of 0.1 M dithiothreitol (DTT) and 1 µl of 10 mM dNTP mix 
(10mM each of dATP, dGTP, dCTP and dTTP)  were added and the mixture 
incubated at 42oC for 2 min. For the first strand synthesis, 1 µl of 200 U/µl 
Superscript II reverse transcriptase was added and incubated at 42oC for 1 h. The 
second strand synthesis was carried out with the addition of 30 µl second strand 
reaction buffer (100 mM Tris-HCl, pH 6.9, 450 mM KCl, 23 mM MgCl2, 0.75 mM β-
NAD+, 50 mM (NH4)2SO4), 3 µl 10 mM dNTP mix, 1 µl DNA ligase, 4 µl of DNA 
polymerase I and 1 µl of RNase H. After 2 h incubation at 16oC, 2 µl of T4 DNA 
polymerase and 10 µl of 0.5 M EDTA were added to the mixture.  
 
For the clean-up of the double-stranded cDNA, reagents used were all from the 
GeneChip Sample Cleanup Module (Affymetrix). 600 µl of cDNA binding buffer* 
was added to the final double-stranded cDNA synthesis preparation and mixed by 
vortexing for 3 s. The sample was loaded into the cDNA clean-up spin column in a 2 
ml collection tube, and centrifuged for 1 min at 16,000 x g with the flowthrough 
discarded. The spin column was then transferred to a new 2 ml collection tube and 
750 µl cDNA wash buffer*, was used to rinse the column. The caps of the spin 
                                                
* Exact composition of buffer is not provided by the manufacturer. 
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columns were then opened and centrifuged for 5 min at 16,000 x g for 5 min to enable 
the membrane in the column to dry completely. Next the cDNA was eluted with 14 µl 
of cDNA elution buffer*, pipetted directly onto the membrane.  
 
2.11.2 Synthesis and clean-up of biotin-labeled cRNA 
After clean-up of the cDNA, it was used as a template to produce biotinylated cRNA 
by in vitro transcription using T7 RNA polymerase and biotin-labeled nucleotides 
from the Enzo BioArray High Yield RNA transcript labeling kit (Affymetrix). The 
reagents from the kit were added in the following order at room temperature: 
Reagents Volume (µl) 
DEPC-treated water 12  
template cDNA 10 
HY reaction buffer*, (10x liquid concentrate) (Vial 1) 4 
biotin-labeled ribonucleotides (10x liquid concentrate) (Vial 2) 4 
DTT (10x liquid concentrate) (Vial 3) 4 
RNase inhibitor mix (10x liquid concentrate) (Vial 4) 4 
T7 RNA polymerase (20x liquid concentrate) (Vial 5) 2 
Total 40 
 
The tubes were then placed in a 37oC incubator for 4 to 5 h, with gentle mixing of the 
contents of the tube every 30 to 45 min during the incubation. The labeled cRNA 
samples were then stored at –80oC before clean-up. 
 
For the clean-up of biotin-labeled cRNA, the reagents were all from the GeneChip 
Sample Cleanup Module. The cRNA samples were mixed with 60 µl of RNase-free 
water, 350 µl of IVT cRNA binding buffer*, and 250 µl of absolute ethanol. The 
                                                
* Exact composition of buffer is not provided by the manufacturer. 
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mixture was then applied to the IVT cRNA clean-up spin column in a 2 ml collection 
tube, centrifuged for 15 s at 16,000 x g, discarding the flowthrough. Another 500 µl 
IVT cRNA wash buffer* was then pipetted onto the spin column, followed by 15 s 
centrifugation at 16,000 x g. After another wash with 500 µl of 80% ethanol, the caps 
of the column were opened and the columns centrifuged for 5 min at 16,000 x g to dry 
the membranes. The cRNAs were then eluted with 11 µl of RNase-free water, 
followed by a second elution using an additional 10 µl of RNase-free water. 1 µl of 
each sample was added to 49 µl of water and a spectrophotometric analysis was 
carried out to determine the cRNA yield. 
 
2.11.3 Fragmentation of cRNA for target preparation 
The next step was to obtain fragmented cRNA before hybridization onto GeneChip 
probe arrays. 2 µl of fragmentation buffer (200 mM Tris-acetate, pH 8.1, 500 mM 
KOAc, 150 mM MgOAc) (Affymetrix) was added for every 8 µl of RNA solution, 
ensuring that the cRNA was of a concentration of at least 0.6 µg/µl. The 
fragmentation buffer is able to break down full-length cRNA to 35 to 200 base 
fragments by metal-induced hydrolysis. The mixture was then incubated at 94oC for 
35 min and placed on ice following incubation. An aliquot of the fragmented cRNA 
was kept for gel analysis. 
 
                                                
* Exact composition of buffer is not provided by the manufacturer. 
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2.11.4 Target hybridization 
For target hybridization, 15 µg of fragmented cRNA was mixed with the following 
reagents to give a final volume of 300 µl. 
Components of hybridization cocktail Volume (µl) 
control oligo B2 (3 nM) (Affymetrix) 5 
eukaryotic hybridization controls (20x liquid concentrate) 
(Affymetrix)  
15 
herring sperm DNA (10 mg/ml) (Promega, Madison, WI) 3 
acetylated bovine serum albumin (BSA) (50 mg/ml) (Invitrogen) 3 
2x hybridization buffer  
(2x concentrate consisting of 200 mM 2-(N-morpholino) 
ethanesulphonic acid (MES), 2 M [Na+], 40 mM EDTA and 0.02% 
Tween-20) 
150 




The probe arrays were equilibrated to room temperature before use while the above 
hybridization cocktails were heated to 99oC for 5 min in a heat block. Each array was 
wetted by filling it with 100 µl of hybridization buffer (100 mM MES, 1 M [Na+], 20 
mM EDTA and 0.01% Tween-20) through the lower septum. The arrays were then 
incubated at 45oC for 10 min with rotation. The hybridization cocktails at 99oC were 
then transferred to a 45oC oven for 5 min incubation then centrifuged at 16,000 x g for 
5 min to remove any insoluble material from the hybridization mixture. 
 
After incubation of the probe arrays, the hybridization buffer was removed and an 
appropriate volume of hybridization cocktail was added. For the Test3 arrays, 80 µl 
was added while for the U74A chips, 250 µl of hybridization cocktail was added into 
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the probe array cartridges. The arrays were then placed into a 45oC hybridization oven 
(Affymetrix), rotated at 60 rpm and hybridized for 16 h. 
 
2.11.5 Washing and staining procedure 




Components Volume (µl) 
MES stain buffer (200 mM MES, 2 M [Na+] and 0.1% 
Tween-20) 
600 
50 mg/ml acetylated BSA 48 
1 mg/ml SAPE (Molecular Probes, Eugene, OR) 12 
DEPC-treated water 540 
Total 1200 
 
The solution was mixed well and divided into two aliquots of 600 µl each to be used 
for stains 1 and 3 respectively.  
 
The antibody solution mix was prepared as follows: 
Components Volume (µl) 
MES stain buffer (200 mM MES, 2 M [Na+] and 0.1% 
Tween-20) 
300 
acetylated BSA 24 
10 mg/ml normal goat IgG (Sigma) 6 
0.5 mg/ml biotinylated antibody  
(Vector Laboratories, Burlingame, CA) 
3.6 




Using the Affymetrix Fluidics Station 400, the Micro_1v1 Fluidics protocol was 
selected for the Test3 arrays while the EukGE-WS2 Fluidics protocol was selected for 
the U74A GeneChips. The two protocols were as follows: 
 Micro_1v1 EukGE-WS2 
Post Hybridization 
Wash #1 
10 cycles of 2 mixes/cycle with wash A (0.9 M NaCl, 0.06 M 




8 cycles of 15 mixes/cycle 
with wash B (100 mM MES, 
0.1 M [Na+] and 0.01% 
Tween-20) at 50oC. 
4 cycles of 15 mixes/cycle 
with wash B at 50oC. 
Stain The probe array was stained for 10 min in SAPE stain solution 
at 25oC. 
Post Stain Wash 10 cycles of 4 mixes/cycle with wash A at 30oC. 
2nd Stain The probe array was stained for 10 min in antibody solution at 
25oC.  
3rd Stain The probe array was stained for 10 min in SAPE stain solution 
at 25oC 
Final Wash 15 cycles of 4 mixes/cycle with wash A at 35oC. The holding 
temperature was 25oC. 
 
2.11.6 Probe array scan 
After the wash protocols, the arrays were scanned using a G2500A Genearray scanner 
(Agilent Technologies, Palo Alto, CA), with pixel value of 3 µm and wavelength 570 
nm.  
 
2.11.7 Data analysis 
Data from each microarray were scaled to an average intensity of 500 and the relative 
mRNA expression levels were expressed as signal log ratios compared to controls 
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using Affymetrix Microarray Suite 5.0 software. Genes which showed a change of 2-
fold or more with a p-value of 0.05 were identified using Data Mining Tool ver 3.0 
(Affymetrix) and were included in subsequent analyses. The p-values were generated 
by the statistical algorithms contained in Affymetrix’s Microarray Suite 5.0. Each 
gene sequence is probed by a collection of 11-16 probe pairs. The signal intensities of 
each of these probe pairs were used to generate the detection p-value of the gene. For 
the change p-value, each probe pair was compared to the matching probe pair in the 
control array to generate the change significance data. 
 
2.12 Real-time quantitative RT-PCR 
2.12.1 cDNA synthesis by reverse transcription 
Total RNA was extracted using High Pure RNA Isolation Kit with on-column DNase 
treatment according to manufacturer’s specifications (Section 2.8.2). All other 
reagents used were from Applied Biosystems, Foster City, CA. The total RNA 
samples were reverse transcribed using Taqman® reverse transcription reagents. The 
final reverse transcription reaction included 200 ng of total RNA, reverse transcription 
(RT) buffer (50 mM KCl and 10 mM Tris-HCl, pH 8.3), 5.5 mmol/L MgCl2, 0.5 
mmol/L dNTP mixture, 2.5 µmol/L random hexamers, 4U RNase inhibitor and 12.5U 
MultiScribe reverse transcriptase. Reaction conditions were 25oC/10 min, 37oC/60 
min and 95oC/5 min carried out in a thermocycler (PTC-100 Peltier Thermal Cycler) 
using a heated lid to prevent loss by evaporation.  
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2.12.2 Real-time quantitation using Taqman Assay 
Multiplex real-time polymerase chain reaction (PCR) amplification was then carried 
out in the TaqMan®  7000 Sequence Detection System (Applied Biosystems) using 
TaqMan® Universal PCR Master Mix (Applied Biosystems) and gene specific primers 
and probes according to manufacturer’s protocols.  
 
Each reaction volume was 25 µl with the following components: 
Reaction components Volume/well (µl) 
2x Taqman® universal PCR master mix   
(2x liquid concentrate composed of proprietary buffer 
components) 
12.5 
20x assay mix of gene specific primers and probe  
(Applied Biosystems) 
1.25 
20x assay mix of 18S RNA primers and probe as 
endogenous control (Applied Biosystems) 
1.25 
cDNA and DEPC-treated water 10  
(100 ng of cDNA) 
Total  25 
 
The probes were labeled with 6-carboxyfluorescein (FAM) as the reporter fluorescent 
dye at their 5' ends while the 3' ends were labeled with 6-carboxy-tetramethyl-
rhodamine (TAMRA) as the quencher. 18S ribosomal RNA was used as an 
endogenous control and its probe was labeled with reporter dye VIC at the 5’ end 
instead. All primers and probes were synthesized by Applied Biosystems and details 





Gene Primers and probes 
Forward primer     : CGTATGAACAGGAGCTGAAAGATGA 
Reverse primer      : ACCATGACGTGCTCGAAGTG 
Anxa3 
Probe                     : CTTGAAGGGTGATCTCTCT 
Forward primer     : GCTTCGGGAGCACAACAGA 
Reverse primer      : TGGTTTGGAATAGTTGCTCATCA 
COX-2 
Probe                     : TGTGCGACATACTCAAGCAGGAGCATC 
Forward primer     : GGTAAAGACCAAGGATGGATACGT 
Reverse primer      : CTTCCTGCTGCTTCTCTTCATGT 
HSP22 
Probe                     : TTGCCTGAAACTTCC 
Forward primer     : AGAAGCTGCTGCAGGACTT 
Reverse primer      : TCCGGATTGATGCTCTTGTTCAG 
HSP70 
Probe                     : TCGCGCCCGTTGAAG 
Forward primer     : CCAATCGCCGTGCTCATC 
Reverse primer      : GGTCCGCCAGGATCGT 
Npn3 
  
Probe                     : ACCCGGCCAAAGTG 
 
The PCR conditions were: an initial incubation of 50oC/2 min and 95oC/10 min 
followed by 40 cycles of 94°C/15 s and 60°C/1 min. All reactions were carried out in 
triplicate. The threshold cycle, CT, which correlates inversely with the levels of target 
mRNA, was measured as the cycle number at which the reporter fluorescent emission 
exceeded a pre-set threshold level. The amplified transcripts were quantified using the 
comparative CT method as described previously (Livak and Schmittgen, 2001) with 
the formula 2-∆∆CT, where ∆∆CT = [∆CT gene of interest (treated sample) - ∆CT 18S 
rRNA (treated sample)] - [∆CT gene of interest (control sample) - ∆CT 18S rRNA 
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(control sample)]. ∆CT represents the mean CT value of each sample. Data were 
obtained by carrying out at least three independent experiments. 
 
2.13 Western blot analysis 
Cells were lysed in RIPA buffer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM 
EDTA, 1% Nonidet-P 40, 0.5% sodium deoxycholate and 0.1% SDS) containing 
protease inhibitor cocktail tablet (Roche) and the supernatant collected after 
centrifugation at 16,000 x g for 10 min. Protein concentration was determined using 
an RC DC protein assay kit (Bio-Rad Laboratories) according to the manufacturer’s 
standard protocol. Equal amounts of protein (15 µg) were separated by SDS-PAGE 
and transferred to polyvinyl difluoride (PVDF) membranes. After transfer, the blots 
were blocked with 4% skim milk powder and 1% BSA (Sigma) in TBST buffer (50 
mM Tris pH 7.5, 150 mM NaCl and 0.1% Tween-20) for 1 h and then probed with 
appropriate primary antibodies. The primary antibodies used were as follows: active 
caspase 3 antibody (BD Biosciences PharMingen, San Diego, CA), heat shock protein 
70 (Oncogene Research Products, San Diego, CA), heat shock protein 47 (Stressgen 
Biotechnologies, Victoria, BC Canada), cyclooxygenase-2 (COX-2) (Cayman 
Chemical, Ann Arbor, MI), cyclin D1 (Cell Signaling Technology, Beverly, MA), 
heat shock protein 22 (Abcam Ltd, Cambridge, UK) and β-tubulin antibody 
(Cytoskeleton, St. Denver, CO). After overnight incubation with primary antibodies at 
4oC, horseradish peroxidase-conjugated anti-rabbit IgG or anti-mouse IgG was used 
to probe each blot. Signals were detected using chemiluminescence (Pierce 
Biotechnology) and the signal intensity quantified by densitometry using GeneTools 
software, v3.05 (SynGene, Cambridge, UK).  
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2.14 Inoculation of bacterial cultures 
Cryostocks of bacteria containing desired plasmids were streaked onto selective agar 
plates containing either 30 µg/ml kanamycin or 100 µg/ml ampicillin, depending on 
the antibacterial resistance of the plasmid. The plates were incubated overnight at 
37oC to obtain single colonies for starter cultures. 
 
A single colony was picked from the selective plate and inoculated into a starter 
culture of 2-4 ml Luria-Bertani (LB) medium containing the same concentration of 
antibiotics (30 µg/ml kanamycin or 100 µg/ml ampicillin) in a 15 ml tube. This was 
then incubated at 37oC with shaking at 200 rpm (Contherm 1100 Incubator, 
Wellington, NZ) overnight (16 h) for a mini-prep. For midi-prep, a 2 ml starter culture 
was prepared as above, incubated at 37oC for 8 h with shaking at 200 rpm (Contherm 
1100), after which it was diluted into 50 ml LB medium containing 30 µg/ml 
kanamycin and grown overnight for 16 h.  
 
2.15 Isolation of bacterial plasmids 
The GFX Micro Plasmid Prep Kit (Amersham Biosciences, Uppsala, Sweden) was 
used to extract and purify plasmids in 2-4 ml culture volumes. The principle is based 
on the modified alkaline cell lysis method (Sambrook et al., 1989). 
 
The overnight culture was centrifuged at 16,000 x g for 30 s to pellet the cells. After 
removal of the supernatant, the pellet was resuspended with vigorous vortexing in 150 
µl of isotonic solution 1 (100 mM Tris-HCl, pH 7.5, 10 mM EDTA and 400 µg/ml 
RNase I).  Cells were then lysed upon the addition of 150 µl of solution II (1 M 
NaOH and 5.3% SDS), resulting in the denaturation of chromosomal DNA and 
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proteins. 300 µl of solution III* (buffered solution contating acetate and chaotrope) 
was then added to neutralize the pH of the cell lysate. The high concentration of 
chaotropic salt in this solution enhances the binding of plasmid DNA to the glass fibre 
matrix of the GFX column.  After centrifuging at 16,000 x g for 5 min the supernatant 
was transferred to a GFX column. The column was then washed with 450 µl of wash 
buffer*, (Tris-EDTA and ethanol) to remove contaminants and the plasmid DNA was 
then eluted with 50 µl of water.  
 
For plasmid purification from 50 ml cultures, the HiSpeed Plasmid Midi Protocol 
(Qiagen) was followed according to manufacturer’s instructions. This method also 
employs the modified alkaline lysis procedure as described for the mini-prep. Plasmid 
DNA was eluted using a high-salt buffer QF*,, concentrated and desalted with 
isopropanol and then applied to a QIAprecipitator Module. The plasmid DNA was 
then eluted from the QIAprecipitator with TE buffer (10 mM Tris-HCl, pH 8.0 and 1 
mM EDTA).  
 
                                                
* Exact composition of buffer is not provided by the manufacturer. 
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2.16 Reverse transcription of total RNA  for cloning 
RNA extracted using High Pure RNA extraction kit (Section 2.8.2) was reverse 
transcribed to synthesize cDNA using an oligo dT  primer (Promega) and Superscript 
reverse transcriptase II (Invitrogen). The following reagents were added: 
Reagents: Volume (µl) 
DEPC-treated water 6.5 
oligo dT (1 µg/2 µl) 2 
total RNA (~ 1 µg/µl) 2 
Total  10.5 
 
After a 10 min incubation at 70oC, the mixture was placed on ice and spun down. The 
following reagents from Invitrogen were then added: 
Reagents Volume (µl) 
DEPC-treated water 1 
first strand cDNA buffer 
(Section 2.11.1) 
4 
DTT (0.1M) 2 
dNTP (10 mM) 1 
RNasin 0.5 
Total  8.5 
 
The mixture was then incubated at 42oC for 2 min, after which 1 µl of Superscript 
reverse transcriptase II was added. The tube was then heated at 42oC for 60 min 




2.17 Polymerase chain reaction  
PCR was used to amplify and subclone target DNA sequences. The Pfu based 
polymerase, Herculase® enhanced DNA polymerase (Stratagene, La Jolla, CA) was 
used according to manufacturer’s procedure and the following reagents were mixed: 
Reagents Working concentration Volume (µl) 
double distilled water - Top up to 50 µl 
10x Herculase® PCR reaction 
buffer* (10x liquid concentrate)  
1x 5 
dNTP (10 mM) 200 µM 1 
cDNA 100 ng Variable 
forward primer (10 µM) 0.2 µM 1 
reverse primer (10 µM) 0.2 µM 1 
Herculase® polymerase (5U/µl) 2.5 U 0.5 
Total   50 
 
The PCR conditions were as follows:  
1. DNA denaturation at 95oC, 30 s 
2. Primer annealing at primer Tm – 5oC, 30 s 
3. Chain extension at 72oC, 1 min/kb target  
 
A total of 35 cycles was carried out with a final extension of 72oC for 10 min. The 
PCR products were then chilled on ice and a sample was analyzed by electrophoresis 
using an appropriate percentage of agarose gel (Table 2.1).  
 
                                                
* Exact composition of buffer is not provided by the manufacturer. 
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Table 2.1: Appropriate Agarose Concentrations for Effective Separation of 
linear DNA molecules (adapted from Sambrook et al., 1989) 
Agarose  
(% w/v) 
Efficient range of resolution of linear DNA fragments 
(kb) 
0.3 5 – 60 
0.6 1 – 20 
0.7 0.8 – 10 
0.9 0.5 – 7 
1.2 0.4 – 6 
1.5 0.2 – 3 
2.0 0.1 – 2 
 
2.18 DNA gel electrophoresis 
This technique was used to analyze the size of DNA fragments and plasmids 
generated from PCR, restriction enzyme digests as well as for separating DNA 
fragments for cloning. 
 
The appropriate concentration of agarose gel was prepared by dissolving agarose 
(Cambrex, Rockland, ME) in TAE buffer (0.04 M Tris base, 0.02 M glacial acetic 
acid and 0.001 M EDTA) according to Table 2.1 above. The agarose was melted in a 
microwave oven and then cooled to about 60oC before casting.  
 
After the gel had set, it was placed into an electrophoresis tank with sufficient TAE 
buffer to cover the gel until the tops of the wells were submerged. DNA samples were 
then loaded together with an appropriate amount of Blue/Orange 6x concentrated 
loading dye (Promega) containing 500x diluted SYBR Green I (Molecular Probes). 3 
µl of 100 base pair DNA ladder (Promega) and 1 kb DNA ladder (Promega) were also 
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loaded. The gel was then run at 70 V until the bromophenol blue dye of the loading 
buffer had migrated to two-thirds of the gel length. The DNA bands were then viewed 
using a UV-transilluminator as described in Section 2.10.  
 
2.19 Extraction of DNA fragments from agarose gels 
The QIAquick gel extraction kit (Qiagen) was used to extract and purify DNA 
fragments separated by gel electrophoresis. The DNA band of interest was excised 
from the agarose gel under UV light (312 nm at 50% intensity) with a scapel. Excess 
gel was removed and the agarose block was weighed. 3 volumes of buffer QG* were 
added to 1 volume of gel. The mixture was then incubated at 50oC for 10 min to 
dissolve the gel, gently mixing every 3 min. 1 gel volume of isopropanol was then 
added and mixed well. The sample was then added to a QIAquick column to allow the 
DNA to bind. The column was then centrifuged at 16,000 x g for 1 min, discarding 
the flowthrough. 0.75 ml of buffer PE*, was then added to wash the column and 
centrifuged as above. The bound DNA was next eluted by the addition of 30 µl of 
buffer EB*,. The eluted DNA was then checked by agarose gel electrophoresis. 
 
2.20 Restriction enzyme digestion 
Restriction enzyme digestion was carried out typically in a 20 µl reaction volume. 
Restriction enzymes used were either from Promega or New England Biolabs 
(Beverly, MA). The total volume of restriction enzymes used in one reaction must not 
exceed 10% of the reaction volume to prevent star activity, the reduced specificity of 
restriction enzymes resulting in the cleavage of similar sequences not identical to its 
defined recognition sequence, due to high glycerol content.  
                                                
* Exact composition of buffer is not provided by the manufacturer. 
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A typical double digestion reaction mixture for two restriction enzymes having 
compatible restriction enzyme buffers was as follows: 
Reagents Volume (µl) 
sterile, deionized water  15.4 
10x restriction enzyme reaction buffer (10x liquid concentrate)  2 
acetylated BSA, 1 µg/µl  1 
DNA, 1 µg/µl 1 
restriction enzyme 1, 10 U/µl 0.3 
restriction enzyme 2, 10 U/µl 0.3 
Total 20 
 
The mixture was then incubated at 37oC for 1.5 to 2 h. A sample of the product was 
then analyzed using agarose gel electrophoresis. 
 
2.21 Dephosphorylation of 5’ overhangs of vector DNA 
After restriction enzyme digestion of cloning vector plasmid, the phosphate groups 
from both 5’ termini of vector DNA were removed to prevent its recircularization and 
religation. 1 µl of 1 U/µl calf alkaline phosphatase (Promega) was added to 50 µl of 
completed restriction enzyme reaction mixture and incubated at 37oC for 1 h for this 
step. 
 
2.22 Ligation of restriction enzyme digested vector and DNA insert 
Ligation of gel purified (Section 2.17) restriction enzyme digested vector and DNA 




Reagents Volume (µl) 
insert 6 
vector 2 
10x ligase buffer (10x liquid concentrated consisting of 300 mM 
Tris-HCl, pH 7.8, 100 mM MgCl2, 100 mM DTT and 10 mM ATP) 
(Promega)  
2 
1 U/µl T4 ligase (Promega) 1 
deionized water 9 
Total  20 
 
A vector-only control, without the insert was also set up and both tubes were 
incubated overnight at 16oC.  
 
2.23 Transformation of competent cells with ligation reaction mixture 
50 µl of Subcloning Efficiency DH5a (Invitrogen) cells were gently pipetted for one 
transformation into a 1.5 ml microfuge tube pre-chilled on ice. 5 µl of the ligation mix 
was added and mixed gently by tapping. The mixture was then incubated on ice for 30 
min. Next, the cells were heat shocked at 42oC for 45 s on a heat block, followed by 2 
min incubation on ice. 250 µl of room temperature S.O.C medium (Invitrogen) was 
then added and the tube then incubated at 37oC for 1 h shaking at 225 rpm (Contherm 
1100 Incubator). 100 µl and 200 µl of the cell mixture were then spread onto two 
selective agar plates pre-warmed to 37oC. Two different volumes were used so that at 
least one plate would have single colonies well separated from one another. The same 
steps were carried out for the ligation mix from the vector-only control and 200 µl of 
these cells were spread onto another similar selective agar plate. The plates were then 
incubated overnight at 37oC. The vector-only control cells should not give rise to any 
colonies on the selective agar plates. 
54 
2.24 Flow cytometry to analyze DNA content of fixed cells 
2.24.1 Fixation of cells with ethanol 
Differentiated neuroblastoma cell lines for DNA analysis by flow cytometry were first 
fixed with ethanol to permeabilize the cells so as to enable the propidium iodide (PI) 
dye to access the DNA of the cells. The cells were first harvested by trypsinization 
with 0.25% trypsin (Sigma) for 10 min after rinsing with sterile PBS (Gibco). The 
cells were then collected by gentle flushing with 0.5 ml of 50% fetal bovine serum in 
Hanks’ Balanced Salt Solution (HBSS) (Gibco) using 1 ml pipette tips. The cells 
were then centrifuged at 300 x g for 5 min, after which, they were thoroughly 
resuspended in 0.5 ml PBS by repeated pipetting. The cell suspension was then 
transferred into tubes containing ice-cold 70% ethanol and mixed well by pipetting up 
and down a few times. The cells were kept in the fixative overnight at –20oC. 
 
2.24.2 Staining of cells with propidium iodide  
The ethanol-suspended cells were centrifuged at 300 x g for 5 min at 4oC. After the 
ethanol was fully decanted, the cell pellet was resuspended in 2 ml PBS and then 
centrifuged at 500 x g for 5 min at 4oC. After the PBS was removed, the cell pellet 
was resuspended in 500 µl of PI staining solution (0.1% Triton-X 100, 0.02% RNase 
A (Sigma) and 0.002% PI (Sigma) in PBS) and then passed through a 22 gauge needle 
twice. The suspension was then kept in dark at 37oC for 15 min. 
 
2.24.3 Flow cytometry 
The Coulter Elite ESP flow cytometer (Beckman Coulter, Fullerton, CA) was set up 
using a 488 nm argon air cooled laser line and detection of PI emission at red 
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wavelengths. The cell fluorescence was measured and the program WinMDI v2.8 
(Copyright® 1993-1998, Joseph Trotter) was used to analyze the data. 
 
2.25 Caspase 3 activity measurement 
Cells were lysed in buffer containing 10 mM HEPES (pH 7.4), 2 mM EDTA, 5 mM 
DTT and 0.1% (v/v) NP40.  The cell lysate was then frozen and thawed 4 times by 
transferring between a –80oC freezer and 37oC water bath, after which the lysate was 
centrifuged at 16,000 x g for 30 min at 4oC. The protein concentration of the 
supernatants was then measured using RC DC protein assay kit (Bio-Rad Laboratories) 
according to manufacturer’s standard protocol.  Enzymatic reactions were carried out 
in lysis buffer containing 10 µg of protein and 50 µM acetyl-Asp-Glu-Val-Asp-
aminotrifluoromethylcoumarin (Ac-DEVD-AFC) (Alexis® Biochemicals, Lausen, 
Switzerland).  Fluorescent AFC formation was measured at excitation wavelength of 
400 nm and emission wavelength of 505 nm using a plate reader (Molecular Devices 
Spectra MaxGeminiXS, Sunnyvale, CA).   
 
2.26 Statistical analyses 
Comparisons between groups were made using ANOVA with Tukey or LSD post hoc 
comparisons, with values of *p < 0.05 set as statistically significant. Each experiment 
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3. Effects of lactacystin treatment in mouse primary cortical neurons: a 
microarray analysis 
3.1 Introduction 
This chapter presents and discusses the effects of proteasome inhibition by lactacystin 
on mouse primary cortical neurons. Since proteasome inhibition is likely to play a 
contributing role to neurodegeneration and is also able to generate initial 
neuroprotective proteins, a microarray analysis was used to identify differentially 
expressed genes induced by proteasome inhibitors in a primary neuronal culture 
model to enable us to have a clearer idea of the possible pro-apoptotic and anti-
apoptotic pathways activated in this process. 
 
3.2 Effects of lactacystin on primary cortical neurons 
3.2.1 Relative cell viability and cell morphology  
MTT assay results showed that cell viability decreases with increasing lactacystin 
treatment, with about 60% residual cell viability when treated with 1 µM lactacystin 
for 24 h (Fig 3.1). Previous studies using fluorescent DNA binding dyes as well as 
transmission electron microscopy confirmed that treatment with 1 µM lactacystin 
induces an apoptotic phenotype and biochemical changes such as observed by cell 
shrinkage, DNA condensation and chromatin fragmentation (Cheung et al., 2004). Fig 
3.2 shows representative images of control neurons with intact neurites and smooth 
surfaced, oval cell bodies as well as cells treated with 1 µM lactacystin for 24 h. 
Treated cells had fragmented neurites and shrunken cell bodies with a rough surface 














Fig 3.1 Effect of lactacystin on viability of murine primary cortical neurons. 
 
Viability of cultured cortical neurons treated with lactacystin was quantitated using 
the MTT assay. Cell injury was found to be concentration- and time-dependent.  











Fig 3.2 Effects of 1 µM lactacystin treatment for 24 h on the morphology of 
primary cortical neurons (from Cheung et al., 2004).  
 































3.2.2 Activation of caspase 3 and upregulation of heat shock protein 70 
Our Western blot analysis showed that caspase 3 activation occurs in a concentration-
dependent manner (Fig 3.3). A similar dose-dependent increase in caspase 3-like 
protease activity was also  previously observed (Qiu et al., 2000). As reported in other 
cell types (Bush et al., 1997), increased levels of HSP70 upon lactacystin treatment 














Fig 3.3 Western blot analyses of HSP70 expression and detection of active 
caspase 3 in cultured mouse primary cortical neurons treated with lactacystin.   
 
Western blot analyses showed lactacystin treatment induced concentration-dependent, 
increased levels of HSP70 as well as caspase 3 activation. β-tubulin was used as an 
internal control after the membrane was stripped. These findings are representative 
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(µM lactacystin, 24 h) 
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3.3 Microarray analysis of differentially expressed genes upon lactacystin 
treatment 
The Affymetrix Murine U74A Genechip which was used to study the gene expression 
profiles of lactacystin-treated primary cortical neurons contains probes for 12,488 
genes and expressed sequence tags. Based on the criteria described in Section 2.11.7, 
our results show that 228 of these genes were differentially expressed with a fold 
change of 2 or more. These genes were then classified based on their known cellular 
functions as shown in Tables 3.1 – 3.4, together with their corresponding relative fold 
change. These groups include genes encoding molecular chaperones, HSPs as well as 
proteins involved in the UPS, response to oxidative stress, cell cycle regulation, 
apoptosis, transcriptional regulation, proteolysis, intermediary metabolism and 
transport. The three lactacystin treatment conditions were chosen as they reflect 
increasing loss of cell viability (Fig 3.1)- after treatment for 24 h with 0.5 µM 
lactacystin, 24 h with 1 µM lactacystin and 48 h with 1 µM lactacystin, cell viability 
decreased to about 75%, 60% and 40% respectively, relative to control cultures. The 
24 h and 48 h time points for 1 µM lactacystin treatments were selected so as to 
identify genes that demonstrate changes in expression level during cell commitment 
to apoptosis while the 24 h treatments with 0.5 µM lactacystin were to identify genes 
which might be involved in an attempt to attenuate proteasome inhibitor-mediated 
apoptosis.  
 
3.4 Validation of differentially expressed genes identified by microarray analysis 
The upregulation of selected genes with a fold change of 2 or more (Section 2.11.7) 
was validated using real-time RT-PCR and Western blot analysis as described in 
Sections 2.12 and 2.13 respectively. These genes include those of the HSP family as 
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these are likely to play significant roles against proteasome inhibitor-mediated 
apoptosis and cyclooxygenase-2 (COX-2), which had a relatively high fold change on 
the microarrays. Two other highly upregulated genes were annexin A3 (Anxa3) and 
neoplastic progression 3 (Npn3). As not much is known about the functions of these 
genes at present, their expression was also validated by real-time RT-PCR so that 
further studies could be carried out to find out more about them.  
 
As shown in Figs 3.3 and 3.4, Western blot analysis confirmed the upregulation of 
HSP70 and HSP47, with similar expression of both mRNA and protein except for 
HSP70 at 48 h 1µM lactacystin treatment where the protein level was still increased 
although there was no significant change in the amount of mRNA (Fig 3.5). This 
difference could be due to a longer half-life of the protein, thus still being measurable 
even though mRNA levels had normalized. This is likely to be due to the different 
turnover rates of mRNA and protein. On the other hand, neither Western blot nor 
microarray analyses showed any significant change in HSP90 protein or mRNA 
expression levels (data not shown). The protein expression of cyclin D1 was also 
upregulated from the Western blot analysis (Fig 3.4), consistent with the microarray 
results. Data from real-time RT-PCR also agreed with corresponding microarray 
results for the HSP70, HSP22, COX-2, Anxa3 and Npn3 genes in terms of their 
upregulation upon treatment (Fig 3.5). Western blot analysis also demonstrated 
increased levels of COX-2 protein, although this was not quantified by densitometry 







Fig 3.4 Validation of selected upregulated genes from microarray analysis by 
Western blot analyses. 
 
Increased expression of HSP47, cyclin D1 and COX-2 observed from microarray 
analysis was validated using Western blot analysis. β-tubulin was used as an internal 
control after the membrane was stripped. These findings are representative results 





Fig 3.5 A comparison between protein and/or mRNA expression levels using 
Western blot analysis and/or real-time RT-PCR with microarray results for 
selected genes. 
 
Protein and/or mRNA expression levels of HSP70, HSP22, HSP47, COX-2, Anxa3 
and Npn3 were quantitated by densitometry after Western blot analysis and/or by real-
time RT-PCR for comparison with microarray results. Values are mean ± SEM of 
three independent experiments and *p<0.05 (ANOVA with Tukey’s test) compared 
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Initial studies done by us confirmed the observations that proteasome inhibition by 
lactacystin leads to an induction of the molecular chaperone, HSP70 (Bush et al., 
1997). Although the inhibition of the proteasome eventually leads to neuronal 
apoptosis, the upregulation of HSP70 has been shown to have an initial 
neuroprotective effect (Bush et al., 1997). In order to identify other differentially 
expressed genes of relevance in both neuroprotection and apoptosis, a global gene 
expression analysis using DNA microarrays (U74A Affymetrix Genechips) was 
performed on murine primary cortical neurons treated with lactacystin in a time- and 
concentration-dependent manner.   
 
The results of the microarray analysis showed changes in gene expression both at 
different time points (24 h and 48 h) after lactacystin treatment, as well as at different 
lactacystin treatment concentrations (0.5 µM and 1 µM). Genes that were 
differentially upregulated at the early time point but not when most cells were 
undergoing apoptosis (48 h 1 µM) could be involved in an attempt to reverse 
proteasome inhibitor-mediated apoptosis. Such genes include the molecular 
chaperones HSP70 and HSP22, genes of the UPS and cell cycle inhibitors such as 
cyclin-dependent kinase inhibitor 1A (p21) and B-cell translocation gene. On the 
other hand, some genes were increasingly or consistently upregulated up until the late 
time point of 48 h 1 µM lactacystin treatment. These include the cathepsins, genes 
involved in apoptosis, oxidative stress and inflammatory response. The observation 
that these genes were highly upregulated at the late time point suggests that they are 
unlikely to exert a neuroprotective effect or may indeed be involved in apoptosis.  
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3.5.1 Ubiquitin proteasome system 
One group of genes upregulated in response to lactacystin treatment was that of the 
UPS. Various genes encoding proteasome subunits were upregulated by 2- to 3-fold 
after 1 µM lactacystin treatment for 24 h (Table 3.1). These results are consistent with 
previous observations  using primary cultures of rat vascular smooth muscle cells 
(Meiners et al., 2003). The expression of the proteasome subunits was not elevated 
significantly after 48 h 1 µM lactacystin treatment. This initial upregulation of 
proteasomal subunits could be due to a regulatory feedback mechanism trying to 
reverse the effects of proteasome inhibition. A similar stress response leading to 
increased levels of proteasome core subunit proteins and mRNAs has also been 
reported in cultured neurons treated with low levels of proteasome inhibitors (Lee et 
al., 2004). 
 
3.5.2 Heat shock proteins and molecular chaperones 
The HSPs and molecular chaperones are another group of genes possibly involved in 
an initial protective response. The upregulation of HSP70 upon proteasome inhibition 
is well documented and has been observed in Madin-Darby canine kidney (Bush et al., 
1997), U937 lymphoid and 293 kidney human tumour cells (Meriin et al., 1998). The 
anti-apoptotic effects of HSP70 are also well established. HSP70 has been reported to 
regulate Bid-dependent apoptosis by inhibiting the cleavage and hence activation of 
Bid, a pro-apoptotic member of the Bcl-2 family (Gabai et al., 2002), the active form 
of which would otherwise cause a Bax-dependent release of pro-apoptotic factors 
from the mitochondria (Li et al., 1998; Luo et al., 1998). Studies have also shown that 
HSP70 can associate directly with Apaf-1, downstream of cytochrome c release from 
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the mitochondria, thus preventing the formation of a functional apoptosome and also 
the activation of initiator caspase procaspase 9 (reviewed by Beere, 2004).  
 
In the case of the small HSP22 and HSP47 however, their upregulation upon 
proteasome inhibition in murine primary cortical neurons have not been previously 
published. These members of the HSP family are stress-inducible and for HSP22, a 
recently identified mammalian small HSP, its physiological function is yet to be fully 
determined. As shown in Fig 3.5 and Table 3.1, the expression of HSP22 gene 
increased quickly initially (3.27 ± 0.61 fold at 24 h 0.5 µM lactacystin treatment and 
5.55 ± 0.37 fold at 24 h 1 µM treatment) and then decreased to 2.84 ± 0.95 fold after 
48 h when more than 50% of the cells were undergoing apoptosis. The other 
differentially expressed HSP was HSP47, a collagen chaperone selectively expressed 
in the endoplasmic reticulum of collagen-synthesizing cells (Nagata, 1998). When 
associated physically with procollagen molecules within the endoplasmic reticulum, 
HSP47 stabilizes procollagen monomers and modulates their transfer to Golgi 
apparatus before export from the cell (Smith et al., 1995). A concomitant increase in 
expression of procollagens IV and V was also observed in this study. As the 
expression of HSP47 remained relatively high (3.61 ± 0.8 fold) at 48 h 1 µM 
lactacystin treatment, it is possible that it may not play a significant protective role 
against apoptosis in neurons.  
 
3.5.3 Response to oxidative stress 
The antioxidants are another group of differentially expressed genes which confer 
protective functions (Table 3.1). These include metallothionein (MT-) I and II (both 
upregulated by about 2-fold at 24 h 0.5 µM lactacystin treatment and then by 4.47 ± 
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0.82 and 2.95 ± 0.49 fold respectively at 48 h 1 µM lactacystin treatment) as well as 
peroxiredoxins 1 (upregulated 2.81 ± 0.10 fold at 24 h 1 µM lactacystin treatment), 6 
(upregulated 3.20 ± 0.80 fold at 48 h 1 µM lactacystin treatment) and thioredoxin 
reductase 1 (upregulated 2.20 ± 0.10 fold at 24 h 1 µM lactacystin treatment). The 
upregulation of MTs in response to various forms of brain injury both in experimental 
models (reviewed by Hidalgo et al., 2001) as well as in the early stages of AD (Adlard 
et al., 1998) has been previously reported. Both MT-1 and MT-II have also been 
observed to be neuroprotective in focal cerebral ischemia (Chae et al., 1994; van 
Lookeren Campagne et al., 1999) and to reduce inflammatory response (Penkowa and 
Hidalgo, 2001). On the other hand, peroxiredoxins and thioredoxin reductase may 
have an important function in the removal of intracellular hydrogen peroxide (Kang et 
al., 1998; Trendelenburg et al., 2002). Thus the upregulation of these genes could 
conceivably be an attempt to defend against oxidative stress due to ROS and RNS as 
well as against the effects of inflammation. 
 
3.5.4 Cell cycle regulation 
Some genes involved in the regulation of cell cycle were also found to be upregulated 
(Table 3.1). Proteasome inhibitor-mediated apoptosis has been shown to require the 
activation of cell-cycle elements at the G1/S interphase (Rideout et al., 2003). When a 
specific inhibitor of cyclin-dependent kinases (Cdks), flavopiridol was applied 
together with lactacystin, proteasomal inhibition-induced apoptotic death was 
prevented. Similarly the molecular inhibitors of Cdk2, Cdk4 and Cdk6 were found to 
improve neuronal survival against lactacystin-mediated cell death (Rideout et al., 
2003). Thus the upregulation of Cdk inhibitor 1A, p21 could be regarded as a 
neuroprotective response to stop the aberrant activation of Cdks. p21 has been 
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implicated both in G1/S (Deng et al., 1995) and G2/M (Chan et al., 2000) cell cycle 
arrest. In addition, since cyclin D1 is a substrate of the proteasome (Pagano, 1997), its 
protein level would be expected to rise following lactacystin treatment, as was shown 
in the Western blot analysis both at 24 h and 48 h after lactacystin treatment (Fig 3.4). 
This was similar to previous observations (Rideout et al., 2003). However, cyclin D1 
was not identified as one of the differentially expressed genes from the microarray 
analysis as the criteria set eliminated genes with fold changes of less than 2 while the 
transcriptional level of cyclin D1 increased by 1.75 ± 0.28 times at 24 h 1 µM and 
1.56 ± 0.05 times at 48 h 1 µM lactacystin treatment, with no significant change at the 
0.5 µM treatment after 24 h. Growth arrest- and DNA damage-inducible gene 45a 
(Gadd45a) and Gadd45b are two other genes of interest in this group, both of which 
were differentially upregulated as compared to the control samples. They are able to 
inhibit Cdk1/cyclin B1 complex activity (Vairapandi et al., 2002) which plays an 
important role in G2/M cell cycle progression (O'Connor, 1997). In addition, both the 
Gadd45 proteins have been shown to interact with p21 (Vairapandi et al., 2002). 
 
3.5.5 Transcription regulation  
Growth arrest- and DNA damage-inducible gene 153 (Gadd153), activating 
transcription factor 3 (ATF3) and CCAAT/Enhancer binding protein (C/EBP) beta 
and delta are all stress-inducible transcription factors of the C/EBP family (Fawcett et 
al., 1999) upregulated in this microarray study (Table 3.2). Depending on its binding 
partners, ATF3 can function either as a transcription activator or repressor. It has been 
shown to induce apoptosis in Hela-S3 and HT1080 cell lines (Mashima et al., 2001) 
while other studies showed that its overexpression can suppress transforming growth 
factor-alpha-induced apoptosis in HUVEC cells (Kawauchi et al., 2002). ATF3 
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expression and c-Jun NH2-terminal kinase (JNK) activation in motor neurons were 
found to inhibit JNK-induced apoptosis by inducing neuroprotective HSP27 which 
could activate the Akt pathway (Nakagomi et al., 2003). However upregulation of 
HSP27 was not observed in our studies on mouse primary cortical neurons. Whether 
ATF3 acts as an anti-apoptotic or pro-apoptotic mediator appears to depend on the 
cell type as well as its binding partner. The identity of the binding counterpart of 
ATF3 in cortical neurons needs to be confirmed. 
 
3.5.6 Apoptosis  
Proteasomal inhibition ultimately leads to apoptosis and one of the apoptotic 
pathways activated is the inflammatory pathway. This is manifested by the increase in 
both COX-2 mRNA and protein levels (Figs 3.4 and 3.5), an observation consistent 
with results using HT4 cells (Rockwell et al., 2000). The proinflammatory 
prostaglandin PGE2, one of the products of COX-2 from arachidonic acid was also 
found to be upregulated upon proteasome inhibition (Rockwell et al., 2000). As 
shown in Fig 3.3, lactacystin-mediated apoptosis has been reported to be accompanied 
by the activation of caspase 3 (Pasquini et al., 2000). The upregulation of the 
cathepsins C, Z and D (Table 3.1) is also of interest as lysosomal cathepsins have 
been shown to play a role in apoptotic death signaling (reviewed by Ferri and 
Kroemer, 2001). Cathepsin D was also recently shown to be involved in ceramide-
induced apoptosis, being upstream of Bid cleavage and the release of cytochrome c 
followed by caspase 9 and 3 activation (Heinrich et al., 2004). Other differentially 




3.5.7 Other genes of interest 
Two other genes of interest are Anxa3 and Npn3. Both these genes were relatively 
highly upregulated upon lactacystin treatment (Table 3.4), and their upregulation was 
also validated using real-time RT-PCR (Fig 3.5). As their physiological functions are 
yet to be determined, these two genes were selected for further studies in this project 
to find out their possible role in neuronal apoptosis upon proteasome inhibition. 
  
3.6 Conclusion 
A microarray study with samples treated at different lactacystin concentrations and 
time points was used to identify genes involved both in an initial putative 
neuroprotective response to proteasome inhibitor treatment as well as those in 
proteasome inhibitor-mediated apoptosis. A consequence of proteasome inhibition is 
the accumulation of misfolded and oxidized proteins which leads to further 
proteasomal dysfunction, resulting in even more oxidative stress and inflammatory 
mediators like COX-2 (reviewed by Li et al., 2003). COX-2 activity generates ROS 
and other neurotoxic prostaglandins as byproducts causing a putative toxic positive 
feedback loop (reviewed by Halliwell, 2001; Halliwell, 2002; reviewed by Li et al., 
2003). Hence the upregulation of HSPs could protect cells against the harmful effects 
described above by preventing protein misfolding, thus reducing the formation of 
such protein aggregates. HSP70 has also previously been shown to act as an anti-
apoptotic agent by inhibiting active caspase 3 as well as preventing the translocation 
of Bax to the mitochondria (reviewed by Benn and Woolf, 2004). The increase in 
expression of HSP22, a novel HSP identified in this study appears to be specific to 
proteasome inhibitor-mediated neuronal death (Section 4.2) and its possible role in the 
regulation of apoptosis was further studied as described in Chapter 4. Other genes that 
counter the effects of inflammation, oxidative stress and possibly aberrant activation 
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of cell cycle proteins were also differentially upregulated upon proteasome inhibition. 
The increase in proteasome subunit mRNA levels could well be due to a feedback 
mechanism attempting to overcome the decreased protein turnover. Eventually when 
the anti-apoptotic mechanisms of the cell are overcome, neuronal cell death possibly 
occurs via inflammation and/or oxidative stress and/or the deviant activation of cell 
cycle proteins, since the differential upregulation of these genes was maintained even 
after 48 h of lactacystin treatment. A possible scheme of proteasome inhibitor-
mediated events leading to neuronal apoptosis is depicted in Fig 3.6. 
 
Data from the microarray analysis demonstrate for the first time, to our knowledge, 
the upregulation of small HSP22 and HSP47, Anxa3 and Npn3 in proteasome 
inhibitor-mediated neuronal apoptosis in murine primary cortical neurons. Further 
















Fig 3.6 A possible scheme of proteasome inhibitor-mediated events leading to 
neuronal apoptosis.  
 
Both neuroprotective and pro-apoptotic response pathways are activated by 
proteasome inhibition via various transcription factors as shown in this diagram, 
summarizing how the anti-apoptotic response attempts to counteract the pro-apoptotic 
response. When the latter fails, apoptosis occurs possibly via inflammatory pathways 












(0.5 L = 0.5 µM lactacystin treatment; 1 L = 1 µM lactaycstin treatment; 2 L = 2 µM 







Table 3.1: Differentially expressed genes from microarray analysis
A ccessio n N o . Gene T it le Gene Symbo l
H eat sho ck pro te ins and mo lecular chapero nes
NM _008908 peptidylpro lyl isomerase C Ppic 1.38 ± 0.10 1.77 ± 0.17 2.39 ± 0.10
NM _030704 crystallin, alpha C (HSP22) Cryac 3.27 ± 0.61 5.55 ± 0.37 2.84 ± 0.95
NM _008303 heat shock protein 1 (chaperonin 10) Hspe1 1.40 ± 0.02 2.08 ± 0.03 1.24 ± 0.08
BC054782 heat shock protein 1A (HSP70) Hspa1a 3.58 ± 0.95 13.60 ± 3.62 1.32 ± 1.21
NM _009825 heat shock protein 47 Serpinh1 2.83 ± 0.32 5.91 ± 0.66 3.61 ± 0.80
Ubiquit in pro teaso me system
NM _008947 pro tease 26S subunit, ATP ase 1 Psmc1 1.64 ± 0.10 2.11 ± 0.02 -0.41 ± 0.72
NM _178616 pro teasome 26S subunit, non-ATPase, 11 Psmd11 1.74 ± 0.25 2.67 ± 0.20 1.20 ± 0.13
NM _008948 pro teasome 26S subunit, ATPase 3 Psmc3 1.98 ± 0.20 2.46 ± 0.04 0.42 ± 0.73
NM _011969 pro teasome subunit, alpha type 7 Psma7 1.72 ± 0.03 2.30 ± 0.10 0.31 ± 0.76
NM _011971 pro teasome subunit, beta type 3 Psmb3 2.35 ± 0.12 3.01 ± 0.24 1.21 ± 0.13
NM _011970 pro teasome subunit, beta type 2 Psmb2 1.90 ± 0.10 2.42 ± 0.04 -0.36 ± 0.70
NM _008951 pro teasome 26S subunit, non-ATPase, 4 Psmd4 1.84 ± 0.16 2.45 ± 0.09 0.40 ± 0.72
NM _011188 pro teasome 26S subunit, ATPase 2 Psmc2 1.65 ± 0.21 2.40 ± 0.14 -1.09 ± 0.00
NM _011967 pro teasome subunit, alpha type 5 Psma5 1.73 ± 0.13 2.16 ± 0.05 1.14 ± 0.06
P ro t eo lysis
NM _009982 cathepsin C Ctsc 5.01 ± 1.35 9.31 ± 2.16 5.48 ± 1.85
NM _022325 cathepsin Z Ctsz 2.09 ± 0.22 2.64 ± 0.22 2.28 ± 0.51
NM _009983 cathepsin D Ctsd 1.82 ± 0.12 2.04 ± 0.11 2.09 ± 0.32
NM _008605 matrix metalloproteinase 12 M mp12 0.91 ± 1.16 3.41 ± 0.99 3.81 ± 0.84
R egulat io n o f  ce ll cycle
NM _008885 peripheral myelin pro tein Pmp22 1.24 ± 0.06 1.50 ± 0.22 2.03 ± 0.15
NM _009831 cyclin G1 Ccng1 1.72 ± 0.12 2.73 ± 0.47 2.43 ± 0.20
NM _009538 pleiomorphic adenoma gene-like 1 Plagl1 1.36 ± 0.13 1.76 ± 0.29 2.04 ± 0.18
NM _010786 transformed mouse 3T3 cell double minute 2 M dm2 1.31 ± 0.06 2.33 ± 0.08 1.41 ± 0.08
NM _008563 minichromosome maintenance deficient 3 M cm3 0.53 ± 0.83 1.47 ± 0.04 2.16 ± 0.32
NM _008565 minichromosome maintenance deficient 4 homolog M cm4 0.41 ± 0.71 1.25 ± 0.01 2.02 ± 0.09
NM _007669 cyclin-dependent kinase inhibito r 1A (P21) Cdkn1a 1.91 ± 0.01 2.90 ± 0.06 1.81 ± 0.22
NM _011313 S100 calcium binding protein A6 (calcyclin) S100a6 1.29 ± 0.02 1.85 ± 0.34 3.27 ± 0.43
NM _007836 growth arrest and DNA-damage-inducible 45 alpha Gadd45a 1.85 ± 0.24 4.17 ± 0.30 2.10 ± 0.20
NM _008655 growth arrest and DNA-damage-inducible 45 beta Gadd45b 7.59 ± 1.61 20.61 ± 2.31 4.09 ± 0.23
NM _009770 B-cell translocation gene 3 Btg3 1.82 ± 0.25 4.17 ± 0.14 1.79 ± 0.14
Gro wt h facto r
NM _010518 insulin-like growth factor binding pro tein 5 Igfbp5 1.23 ± 0.06 -1.14 ± 0.04 2.23 ± 0.09
NM _011819 growth differentiation facto r 15 Gdf15 9.07 ± 3.26 16.31 ± 3.89 3.58 ± 2.27
NM _010516 cysteine rich pro tein 61 Cyr61 1.82 ± 0.11 2.98 ± 0.66 3.57 ± 0.07
NM _008760 osteoglycin Ogn 1.55 ± 0.29 1.45 ± 0.23 4.13 ± 0.20
Inf lammato ry respo nse
NM _008483 laminin, beta 2 Lamb2 1.18 ± 0.07 1.53 ± 0.07 2.32 ± 0.09
NM _013737 phospholipase A2, group VII P la2g7 -0.40 ± 0.70 -1.49 ± 0.21 2.35 ± 0.20
NM _011198 prostaglandin-endoperoxide synthase 2 (COX-2) Ptgs2 2.60 ± 0.15 11.47 ± 0.00 5.49 ± 1.46
R espo nse t o  o xidative  stress
NM _010357 glutathione S-transferase, alpha 4 Gsta4 3.28 ± 0.50 4.48 ± 0.37 5.04 ± 1.42
NM _011034 peroxiredoxin 1 Prdx1 2.34 ± 0.18 2.81 ± 0.10 1.71 ± 0.21
NM _008630 metallo thionein 2 M t2 1.88 ± 0.03 2.06 ± 0.22 2.95 ± 0.49
NM _010497 isocitrate dehydrogenase 1 (NADP+), so luble Idh1 -1.51 ± 0.06 -2.05 ± 0.01 -1.55 ± 0.06
NM _013602 metallo thionein 1 M t1 2.10 ± 0.04 2.57 ± 0.46 4.47 ± 0.82
NM _007453 peroxiredoxin 6 Prdx6 1.57 ± 0.08 1.63 ± 0.49 3.20 ± 0.80
NM _015762 thio redoxin reductase 1 Txnrd1 1.40 ± 0.13 2.20 ± 0.10 1.25 ± 0.07







(0.5 L = 0.5 µM lactacystin treatment; 1 L = 1 µM lactaycstin treatment; 2 L = 2 µM 






Table 3.2: Differentially expressed genes from microarray analysis (cont'd)
A ccessio n N o . Gene T it le Gene Symbo l
A po pto sis
NM _009538 pleiomorphic adenoma gene-like 1 Plagl1 1.36 ± 0.13 1.76 ± 0.29 2.04 ± 0.18
AA260005 PRKC, apoptosis, WT1, regulato r Pawr 1.50 ± 0.13 2.43 ± 0.22 3.03 ± 0.32
NM _146057 death-associated pro tein Dap 1.57 ± 0.10 2.13 ± 0.06 1.97 ± 0.03
NM _022032 PERP, TP53 apoptosis effecto r Perp 1.75 ± 0.15 2.98 ± 0.17 2.28 ± 0.22
NM _008234 helicase, lympho id specific Hells 0.45 ± 0.78 1.29 ± 0.07 2.01 ± 0.11
NM _013863 Bcl2 associate athanogene Bag3 2.02 ± 0.10 4.81 ± 0.83 4.75 ± 1.14
C yto kine
NM _024217 chemokine-like facto r super family 3 Cklfsf3 0.95 ± 1.08 2.52 ± 0.20 2.19 ± 0.29
NM _008047 fo llistatin-like 1 Fstl1 1.25 ± 0.06 1.66 ± 0.14 1.99 ± 0.21
NM _016740 S100 calcium binding protein A11 (calizzarin) S100a11 3.01 ± 0.20 4.97 ± 0.33 6.90 ± 0.84
C ell mo tility
NM _007725 calponin 2 Cnn2 1.91 ± 0.35 2.52 ± 0.56 2.38 ± 0.41
NM _009215 somatostatin Sst -1.05 ± 0.01 -1.30 ± 0.11 -3.73 ± 0.64
Signal T ransductio n
NM _015756 shroom Shrm 1.36 ± 0.13 1.92 ± 0.28 2.84 ± 0.16
NM _007918 eukaryo tic translation initiation facto r 4E binding pro tein Eif4ebp1 1.32 ± 0.07 2.40 ± 0.27 1.63 ± 0.25
NM _011019 oncostatin M  receptor Osmr 2.27 ± 0.08 3.92 ± 0.27 3.60 ± 0.67
NM _010070 downstream o f tyrosine kinase 1 Dok1 2.37 ± 0.26 3.67 ± 0.49 1.28 ± 0.11
NM _023456 neuropeptide Y Npy -1.98 ± 0.21 -2.85 ± 0.16 -2.92 ± 0.13
NM _011368 A kinase (PRKA) anchor pro tein (gravin) 12 Akap12 1.34 ± 0.06 2.49 ± 0.08 1.23 ± 0.08
NM _010415 visinin-like 1 Vsnl1 -1.34 ± 0.10 -1.99 ± 0.04 -2.19 ± 0.27
NM _012038 diphtheria toxin receptor Dtr 1.37 ± 0.12 2.69 ± 0.13 1.29 ± 0.06
NM _010217 SH2 domain-containing transforming pro tein C1 Shc1 1.41 ± 0.10 1.94 ± 0.07 1.66 ± 0.04
NM _031185 moesin M sn 2.56 ± 0.19 4.48 ± 0.06 3.97 ± 0.57
NM _010200 fibroblast growth factor 13 Fgf13 -1.62 ± 0.18 -2.35 ± 0.31 -1.24 ± 0.20
T ranscript io nal regulat io n
NM _007837 DNA-damage inducible transcript 3 (Gadd153) Ddit3 0.49 ± 0.75 2.79 ± 0.21 0.43 ± 0.73
NM _009372 TG interacting facto r Tgif 1.65 ± 0.21 3.23 ± 0.27 2.78 ± 0.48
NM _007498 activating transcription facto r 3 Atf3 1.70 ± 0.21 6.48 ± 1.86 2.07 ± 0.51
BC054830 striamin Strm 1.39 ± 0.09 2.04 ± 0.05 1.83 ± 0.17
M m.294885 cellular repressor of E1A-stimulated genes Creg 1.88 ± 0.25 2.50 ± 0.25 1.51 ± 0.23
NM _007679 CCAAT/enhancer binding pro tein (C/EBP), delta Cebpd 1.71 ± 0.07 2.96 ± 0.62 2.80 ± 0.23
NM _010234 FBJ osteosarcoma oncogene Fos 1.50 ± 0.27 2.81 ± 0.20 2.44 ± 0.07
NM _010902 nuclear, facto r, erythro id derived 2, like 2 Nfe2l2 1.97 ± 0.30 2.68 ± 0.03 3.34 ± 0.54
NM _009883 CCAAT/enhancer binding pro tein (C/EBP), beta Cebpb 1.44 ± 0.14 3.55 ± 0.16 1.46 ± 0.13
NM _010441 high mobility group AT-hook 2 Hmga2 1.83 ± 0.32 3.69 ± 0.13 2.38 ± 0.85
NM _017375 SH3 domain pro tein 3 Sh3d3 1.77 ± 0.18 2.34 ± 0.04 1.39 ± 0.16
NM _010235 fos-like antigen 1 Fosl1 8.43 ± 1.23 21.27 ± 0.39 8.06 ± 2.53
C ell adhesio n
NM _011580 thrombospondin 1 Thbs1 1.45 ± 0.07 2.39 ± 0.17 3.08 ± 0.40
NM _011693 vascular cell adhesion molecule 1 Vcam1 0.77 ± 0.91 2.39 ± 0.74 4.70 ± 0.33
NM _007737 proco llagen, type V, alpha 2 Col5a2 1.18 ± 0.04 1.61 ± 0.17 2.86 ± 0.45
NM _007736 proco llagen, type IV, alpha 5 Col4a5 1.22 ± 0.04 1.28 ± 0.07 2.24 ± 0.14
NM _010217 connective tissue growth facto r Ctgf 8.39 ± 5.06 27.42 ± 18.51 11.68 ± 5.33
NM _009818 catenin alpha 1 Catna1 1.52 ± 0.12 2.06 ± 0.07 2.17 ± 0.14
NM _010705 lectin, galactose binding, so luble 3 Lgals3 2.71 ± 0.19 8.66 ± 2.09 10.05 ± 3.96
NM _008495 lectin, galactose binding, so luble 1 Lgals1 2.07 ± 0.15 3.94 ± 1.12 7.01 ± 0.50
24hr 0.5L 24hr 1L 48hr 1L
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(0.5 L = 0.5 µM lactacystin treatment; 1 L = 1 µM lactaycstin treatment; 2 L = 2 µM 




Table 3.3: Differentially expressed genes from microarray analysis (cont'd)
A ccessio n N o . Gene T it le Gene Symbo l
C arbo hydrate metabo lism
NM _010685 lysosomal membrane glycopro tein 2 Lamp2 1.79 ± 0.22 2.48 ± 0.03 2.56 ± 0.37
NM _008155 glucose phosphate isomerase 1 Gpi1 2.56 ± 0.18 2.80 ± 0.12 1.21 ± 0.04
NM _010283 glycopro tein galactosyltransferase alpha 1, 3 Ggta1 1.29 ± 0.02 1.42 ± 0.02 1.95 ± 0.24
NM _145937 ribosomal protein L36 Rpl36 1.98 ± 0.22 2.50 ± 0.27 2.04 ± 0.06
NM _146108 RIKEN cDNA 2610509I15 gene 2610509I15Rik 1.48 ± 0.09 2.08 ± 0.06 1.54 ± 0.23
NM _008896 paraoxonase 2 Pon2 1.35 ± 0.06 1.68 ± 0.06 2.35 ± 0.21
NM _008129 glutamate-cysteine ligase , modifier subunit Gclm 1.63 ± 0.24 2.91 ± 0.14 1.51 ± 0.21
M m.7729 aldo lase 3, C iso form Aldo3 -1.37 ± 0.15 -2.60 ± 0.24 1.34 ± 0.10
NM _010497 isocitrate dehydrogenase 1 (NADP+), so luble Idh1 -1.51 ± 0.06 -2.05 ± 0.01 -1.55 ± 0.06
NM _010344 glutathione reductase 1 Gsr 2.25 ± 0.41 2.88 ± 0.20 0.56 ± 0.80
NM _019946 microsomal glutathione S-transferase 1 M gst1 2.82 ± 0.26 3.75 ± 0.39 3.27 ± 0.58
NM _013820 hexokinase 2 Hk2 2.32 ± 0.39 7.42 ± 4.13 0.41 ± 0.73
NM _024255 RIKEN cDNA 2610207I16 gene 2610207I16Rik 1.28 ± 0.03 1.35 ± 0.27 2.49 ± 0.44
NM _009121 spermidine/spermine N1-acetyl transferase 1 Sat1 1.72 ± 0.21 3.45 ± 0.31 1.82 ± 0.32
Electro n transpo rt
NM _008483 laminin, beta 2 Lamb2 1.18 ± 0.07 1.53 ± 0.07 2.32 ± 0.09
NM _028057 RIKEN cDNA 1500005G05 gene 1500005G05Rik 1.84 ± 0.12 3.38 ± 0.15 1.28 ± 0.17
NM _008706 NAD(P )H dehydrogenase, quinone 1 Nqo1 2.93 ± 0.44 3.51 ± 0.16 4.81 ± 1.39
NM _020010 cytochrome P450, 51 Cyp51 -2.35 ± 0.28 -3.30 ± 0.06 -2.88 ± 0.04
NM _007806 cytochrome b245 alpha po lypeptide Cyba 0.17 ± 1.20 2.54 ± 1.39 3.14 ± 0.12
NM _009994 cytochrome P450 family 1 subfamily b polypeptide 1 Cyp1b1 -0.48 ± 0.86 1.27 ± 0.19 2.97 ± 0.32
C yto skeletal pro te ins
NM _022410 myosin heavy chain IX M yh9 1.52 ± 0.26 2.48 ± 0.18 1.82 ± 0.04
M m.22448 cytoskeleton associated pro tein 2 Ckap2 1.30 ± 0.05 1.48 ± 0.01 2.19 ± 0.14
NM _007392 actin, alpha 2, smooth muscle, aorta Acta2 1.58 ± 0.05 2.73 ± 1.18 5.47 ± 1.08
NM _010354 gelso lin Gsn 1.48 ± 0.04 1.55 ± 0.12 2.36 ± 0.17
M m.271770 myosin, light po lypeptide 9, regulatory M yl9 1.42 ± 0.16 1.53 ± 0.42 2.52 ± 0.33
NM _013750 pleckstrin homology-like domain, family A, member 3 Phlda3 1.69 ± 0.09 2.75 ± 0.59 1.87 ± 0.31
NM _019390 lamin A Lmna 1.90 ± 0.32 3.17 ± 0.10 1.39 ± 0.08
T ranspo rt
NM _011125 phospholipid transfer pro tein Pltp 1.25 ± 0.03 1.32 ± 0.19 3.05 ± 0.17
NM _009700 aquaporin 4 Aqp4 -1.91 ± 0.15 -4.02 ± 0.14 1.27 ± 0.10
NM _134090 KDEL endoplasmic reticulum protein retention receptor 3Kdelr3 1.38 ± 0.05 2.39 ± 0.08 1.83 ± 0.13
M m.1358 mannose-6-phosphate receptor, cation dependent M 6pr 1.35 ± 0.07 2.00 ± 0.10 1.45 ± 0.05
NM _009306 synapto tagmin 1 Syt1 -0.58 ± 0.86 -2.94 ± 0.25 0.14 ± 1.06
NM _011920 ATP-binding cassette, sub-family G (WHITE), member 2 Abcg2 1.48 ± 0.12 2.62 ± 0.07 1.40 ± 0.19
( Io n transpo rt)
NM _011026 purinergic receptor P2X, ligand-gated ion channel 4 P2rx4 1.58 ± 0.07 2.40 ± 0.48 2.78 ± 0.09
NM _033444 chloride intracellular channel 1 Clic1 1.97 ± 0.04 3.27 ± 0.45 3.52 ± 0.31
NM _178405 ATPase, Na+/K+ transporting, alpha 2 polypeptide Atp1a2 -1.56 ± 0.09 -3.21 ± 0.14 0.40 ± 0.79
Immune respo nse
NM _018734 guanylate nucleotide binding protein 3 Gbp3 1.50 ± 0.09 1.69 ± 0.03 2.20 ± 0.10
NM _008332 interferon-induced pro tein with tetratricopeptide repeats Ifit2 -0.32 ± 0.77 -0.31 ± 0.82 2.31 ± 0.15
NM _025378 RIKEN cDNA 1110004C05 gene 1110004C05Rik 1.40 ± 0.17 0.67 ± 0.92 4.03 ± 0.52
C o agulat io n syst em
NM _011173 pro tein S (alpha) Pros1 2.01 ± 0.04 2.56 ± 0.18 3.75 ± 0.34
NM _010171 coagulation facto r III F3 1.65 ± 0.04 3.41 ± 0.31 2.29 ± 0.11
NM _009673 annexin A5 Anxa5 1.25 ± 0.03 1.65 ± 0.09 2.24 ± 0.09
24hr 0.5L 24hr 1L 48hr 1L
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(0.5 L = 0.5 µM lactacystin treatment; 1 L = 1 µM lactaycstin treatment; 2 L = 2 µM 
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Table 3.4: Differentially expressed genes from microarray analysis (cont'd)
A ccessio n N o . Gene T it le Gene Symbo l
Others /  unkno wn functio ns
NM _007793 cystatin B Cstb 1.47 ± 0.06 2.00 ± 0.30 1.70 ± 0.25
NM _026470 spermatogenesis associated 6 Spata6 0.41 ± 0.71 1.16 ± 0.08 1.96 ± 0.08
NM _011607 tenascin C Tnc 1.43 ± 0.16 2.67 ± 0.32 0.41 ± 0.80
NM _175088 kidney cell line derived transcript 1 Kdt1 1.36 ± 0.05 2.46 ± 0.13 2.33 ± 0.11
NM _133784 RIKEN cDNA 2310058J06 gene 2310058J06Rik 1.49 ± 0.18 2.54 ± 0.31 2.15 ± 0.08
M m.23645 expressed sequence AI843918 AI843918 -1.38 ± 0.11 -2.05 ± 0.03 -1.80 ± 0.10
NM _011638 transferrin receptor Trfr -0.49 ± 0.77 -2.47 ± 0.03 0.35 ± 1.33
NM _026163 RIKEN cDNA 1200008D14 gene 1200008D14Rik 1.55 ± 0.13 2.28 ± 0.21 2.42 ± 0.15
NM _010329 glycopro tein 38 Gp38 1.59 ± 0.07 2.08 ± 0.30 2.76 ± 0.02
NM _010097 SPARC-like 1 (mast9, hevin) Sparcl1 -1.33 ± 0.05 -2.13 ± 0.08 -1.30 ± 0.14
NM _016903 esterase 10 Es10 2.14 ± 0.08 3.29 ± 0.48 2.14 ± 0.36
NM _008515 leucine rich repeat (in FLII) interacting pro tein 1 Lrrfip1 1.52 ± 0.02 3.49 ± 0.15 3.16 ± 1.11
NM _008590 mesoderm specific transcript M est 1.97 ± 0.14 2.49 ± 0.03 2.48 ± 0.13
NM _009221 synuclein, alpha Snca -2.10 ± 0.11 -2.95 ± 0.29 -2.73 ± 0.24
NM _009906 cero id-lipo fuscinosis, neuronal 2 Cln2 1.59 ± 0.06 1.94 ± 0.09 2.48 ± 0.12
NM _029614 RIKEN cDNA 2310046G15 gene 2310046G15Rik 1.61 ± 0.27 1.78 ± 0.14 3.50 ± 0.20
NM _133784 RIKEN cDNA 2310058J06 gene 2310058J06Rik 1.46 ± 0.24 1.80 ± 0.05 2.33 ± 0.16
NM _009254 serine cysteine proteinase inhibito r clade B, member 6a Serpinb6a 1.57 ± 0.08 2.14 ± 0.15 1.46 ± 0.08
NM _025326 RIKEN cDNA 0610011I04 gene 0610011I04Rik 1.91 ± 0.24 1.96 ± 0.36 2.53 ± 0.32
NM _009242 secreted acidic cysteine rich glycopro tein Sparc 1.63 ± 0.08 2.87 ± 0.14 4.11 ± 0.31
NM _007408 adipose differentiation related pro tein Adfp 1.66 ± 0.08 2.75 ± 1.05 4.11 ± 1.46
NM _013470 annexin A3 Anxa3 3.95 ± 0.2 11.1 ± 1.48 10.2 ± 0.95
NM _007585 annexin A2 Anxa2 2.07 ± 0.18 2.8 ± 0.12 1.21 ± 0.04
NM _009673 annexin A5 Anxa5 1.25 ± 0.03 1.65 ± 0.09 2.24 ± 0.09
NM _029688 neoplastic progression 3 Npn3 6.98 ± 2.49 17.4 ± 3.94 3.79 ± 1.9
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4. Study on Heat Shock Protein 22 
4.1 Introduction  
One of the genes identified from the microarray study described in Chapter 3 is 
HSP22. It is a recently identified member of the small HSP (sHSP) family, having the 
hallmark feature called the α-crystallin domain which consists of a highly conserved 
sequence of ~90 amino acid residues in the carboxy-terminal region (Benndorf et al., 
2001). The sHSPs form a large protein family currently made up of 10 different 
members from the human genome (Kappe et al., 2003) (refer Table 4.1). These 
proteins are characterized both by the presence of the α-crystallin domain as well as 
by their relatively low molecular weight (~20–25 kDa). The human HSP22 has been 
found to be highly expressed in skeletal and smooth muscles, heart and brain and also 
has moderate expression in the cervix, prostate, lung and kidneys (Benndorf et al., 
2001). However, its physiological function is yet to be fully determined. A study on 
the overexpression of mitochondrial HSP22 in Drosophila demonstrated that it plays 
a role in cell protection against ageing and oxidative stress (Morrow et al., 2004). It 
has also been  shown to exhibit chaperone-like activity and was able to protect against 
dithiothreitol (DTT)-induced aggregation of insulin and thermal aggregation of citrate 
synthase (Chowdary et al., 2004). Moreover, an association between missense 
mutations in HSP22 with the human neuromuscular disorder distal hereditary motor 
neuropathy was also recently reported (Irobi et al., 2004). Thus HSP22 may be an 
important protective protein, which stood out as an interesting candidate to study in 
terms of its role in the regulation of neuronal apoptosis.   
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This chapter describes further studies done on the upregulation of HSP22 upon 
various apoptotic insults, the cloning of a pIRES2-EGFP-HSP22 clone and the effects 
of its upregulation in various cell lines. 
 
Table 4.1 Known members of human sHSP family and their synonyms (adapted 
from Benndorf et al., 2001)  
sHSP Synonyms 
HSPB1 HSP27, HSP25 (in rodents)  
HSPB2  MKBP, myotonic dystrophy protein kinase binding protein 





HSPB8 HSP22, H11, E21G1 
HSPB9 -  
HSPB10 Sperm outer dense fiber protein 1, ODFP1 
 
 
4.2 HSP22 expression upon various drug treatments 
In order to find out if other apoptotic insults triggered a similar upregulation of 
HSP22, murine primary cortical neurons were treated with various drugs, using 
similar concentrations as has previously been shown to induce cell death by 
apoptosis-  0.5 µM staurosporine (STS) (Koh et al., 1995), 1 µM colchicine (Bonfoco 
et al., 1995), 75 µM hydrogen peroxide (Cheung et al., 2000), 20 µM amyloid beta 1-
40 (Aβ1-40) (Loo et al., 1993), 0.1 µM MG132 (Qiu et al., 2000) and 1 µM lactacystin 
(Cheung et al., 2004). Real-time RT-PCR was carried out and the results indicated 
that only the proteasome inhibitors lactacystin and MG132 gave rise to a significant 
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increase in HSP22 levels (Fig 4.1) although about 50-70% of the cells in each 
treatment appeared injured based on their morphology. This indicates that the 
upregulation of HSP22 does not always accompany neuronal apoptosis and may play 

















         ctr          0.5µM          1µM          0.1 µM       1 µM          75µM           20µM  
                        STS            Colc         MG132        Lac            H2O2        Aβ1-40  
 
Fig 4.1 HSP22 expression upon various drug treatments (24 h). 
 
The expression of HSP22 upon various apoptotic treatments was investigated, 
resulting in only lactacystin (Lac) and MG132 treatments with statistically significant 
upregulation. Values are mean ± SEM of three samples and *p<0.05 (ANOVA with 
Tukey’s test) compared with control. 
 
4.3 Generation of pIRES2-EGFP-HSP22 clone 
The full length cDNA of mouse HSP22 was PCR-amplified from Invitrogen’s 
Ultimate ORF Clone ID IOM 15939 using the forward primer CGG AAT TCA 
TGG CTG ACG GGC AAT TGC CT (EcoRI site underlined) and reversed primer 
CTA CTA GGA ACA GGT GAC TTC CTG. The PCR amplicon was cloned into a 
pIRES2-EGFP vector (Clontech Laboratories Inc., Palo Alto, CA) using its EcoRI and 
SmaI sites (Fig 4.2). The pIRES2-EGFP vector enables HSP22 to be expressed 
together with the enhanced green fluorescent protein (EGFP) from a single bicistronic 
* *
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mRNA. The sequence was confirmed by DNA sequencing (refer to Appendix) and 



















Fig 4.2 Restriction map and multiple cloning site of pIRES2-EGFP vector, 
indicating restriction sites used for cloning pIRES2-EGFP-HSP22. 
 
This diagram shows the unique restriction sites of pIRES2-EGFP in bold, and the 
restriction sites used for cloning pIRES2-EGFP-HSP22 are underlined (adapted from 












Fig 4.3 EcoRI and BamHI restriction enzyme digestion of pIRES2-EGFP-HSP22. 
 
DNA gel electrophoresis of EcoRI and BamHI restriction enzyme digestion products 
shows correct size: ~5.3 kb for vector and ~452 bp for HSP22 insert. Representative 
results from at least three independent experiments. 
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4.4 Effects of transient transfection of pIRES2-EGFP-HSP22 on murine primary 
cortical neurons 
Although primary cortical neurons are notoriously difficult to transfect, preliminary 
experiments using the pEGFP-N3 (Clontech) vector showed that a transfection 
efficiency of about 3-5% could be obtained based on EGFP expression (Fig 4.4). 
However when the same method (Section 2.5) was used for the pIRES2-EGFP vector 
and pIRES2-EGFP-HSP22 plasmid, virtually no expression of EGFP could be 
observed. Thus it is likely that the pIRES2-EGFP plasmid does not transfect well into 
murine primary cortical neurons using this particular transfection system. The HSP22 
insert was not cloned into the pEGFP-N3 vector although this vector can be 
transfected with relatively high efficiency into cortical neurons as the vector would 
then express HSP22 fused to the N-terminus of EGFP. HSP22 being a small protein 
of about 22 kDa is very likely to be affected in terms of its properties by the EGFP 
molecule (~30 kDa) fused to it. Thus a neuronal cell line was used to investigate the 






Fig 4.4 Fluorescence microscopy showing EGFP expression in mouse primary 
cortical neurons. 
 
Murine primary cortical neurons were able to be transfected with pEGFP-N3 vector as 
shown by EGFP expression. 
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4.5 Effects of transient transfection of pIRES2-EGFP-HSP22 on Neuro2a cells 
The mouse neuroblastoma cell line Neuro2a is a clonal strain of C1300 (Augusti-
Tocco and Sato, 1969). These cells can be readily differentiated into neuron-like cells 
with neurite extensions upon application of 20 µM retinoic acid (Section 2.2.2) (Shea 
et al., 1985) for 24 h. Their transfection efficiency was also much higher- about 30-
40% (Fig 4.5), unlike that of primary cortical neurons which were not possible to 
transfect with this plasmid. Thus differentiated Neuro2a cells were chosen as a 
neuronal model to investigate the effects of transient transfection of pIRES2-EGFP-








Fig 4.5 Differentiated Neuro2a cells transfected with pIRES2-EGFP-HSP22.  
 
A: bright field image; B: FITC image. 
 
4.5.1 Western blot analysis to detect active caspase 3 in naïve Neuro2a cells 
Caspase 3 activity was used as a marker to estimate apoptosis because previous 
studies have shown that proteasome inhibitors induced apoptosis through a caspase-
dependent pathway in both neuronal (Canu et al., 2000; Qiu et al., 2000) and non-
neuronal cells (Yamada et al., 2000; Zhang et al., 1999), with caspase 3 being one of 




Upon treatment of naïve Neuro2a cells transfected with pIRES2-EGFP-HSP22 and 
pIRES2-EGFP vector only with the following apoptosis-inducing drugs: 5 µM 
colchicine, 0.25 µM STS, 100 µM H2O2, 500 µM H2O2 and 50 µM Aβ25-35, it was 
found that the morphology of pIRES2-EGFP-HSP22 transfected cells and those 
transfected by pIRES2-EGFP vector only appeared similar. These cells were then 
lysed as described in Section 2.13 and a 12% polyacrylamide gel electrophoresis was 
run followed by Western blot analysis to detect possible differences in the activation 
of caspase 3. 
 
Although about 60-80% of the cells in each treatment appeared injured based on their 
morphology, only those treated with STS and Aβ25-35 showed active caspase 3 in their 
cell lysates (Fig 4.6). From this experiment it appears that there is no observable 
protective effect by HSP22 in undifferentiated Neuro2a cells under these treatments. 
One explanation could be that the possible protective effect of HSP22 does not occur 
in these naïve cells but they could be more specific towards neurons.  
 
4.5.2 Western blot analysis to detect active caspase 3 in differentiated Neuro2a 
cells 
Next naive Neuro2a cells were differentiated for 24 h after transfection (Section 2.2.2) 
to find out if neuron-like cells might demonstrate differences upon lactacystin 
treatment in terms of caspase 3 activation. However Western blot analysis was unable 
to detect activation of caspase 3. Thus it appears that the activation of caspase 3 may 
not be a suitable marker of cell death for this model system. 
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Fig 4.6 Western blot analysis to detect active caspase 3 in transfected naïve 
Neuro2a cells treated with various drugs. 
 
Activation of caspase 3 occurred in both pIRES2-EGFP-HSP22 and pIRES2-EGFP 
transfected naïve Neuro2a cells for 0.25 µM STS and 50 µM Aβ25-35 treatment to a 
similar extent (faint bands of active caspase 3 shown by arrowheads), indicating no 




4.5.3 Viability of naïve and differentiated Neuro2a cells upon MG132 treatment 
Since the expression of HSP22 is increased relatively specifically during proteasome 
inhibitor-mediated apoptosis (Section 4.2), the proteasome inhibitor MG132 was used 
as an insult against the transfected cell lines. In order to find out the suitable 
concentration of MG132 to treat the Neuro2a cells, viabilities of both naïve and 
differentiated Neuro2a cells were measured using the MTT test (Section 2.4). Results 
showed that differentiated cells were more vulnerable as compared to non-
differentiated Neuro2a cells with 0.5 µM MG132 treatment for 24 h causing about 
50% decrease in viability in naive cells (Fig 4.7) while for differentiated Neuro2a 
















Fig 4.7 Viability of naïve Neuro2a cells treated with MG132 (µM/24 h). 
 
Viability (% of control) of non-differentiated Neuro2a cells treated with increasing 
concentrations of MG132 for 24 h, as measured by MTT A570 absorbance. Values are 














Fig 4.8 Viability of differentiated Neuro2a cells treated with MG132 (µM/24 h). 
 
Viability (% of control) of differentiated Neuro2a cells treated with increasing 
concentrations of MG132 for 24 h, as measured by MTT A570 absorbance. Values are 








































4.5.4 MTT test to measure viability of differentiated Neuro2a cells transfected 
with pIRES2-EGFP-HSP22 and pIRES2-EGFP vector only 
After Neuro2a cells were transfected with either the pIRES2-EGFP-HSP22 plasmid or 
vector alone for 24 h, they were differentiated by changing the medium to 
differentiation medium of low serum concentration (Section 2.2.2) and 20 µM retinoic 
acid for 24 h. The cells were then treated with 0.1-0.5 µM MG132 for 24 h. This 
concentration range was chosen as 24 h treatments with 0.1 µM and 0.25 µM MG132 
are likely to cause cell death of up to 50%, based on previous MTT measurements 
(Fig 4.8). Relative cell viabilities were then assessed using the MTT test (Section 2.4). 
As seen from Fig 4.9, there was no significant difference between cells transfected 




















Fig 4.9 Viability of transfected differentiated Neuro2a cells treated with MG132 
(µM/24 h). 
 
Viability (% of control) of differentiated Neuro2a cells measured by MTT test showed 
no significant difference between cells transfected with pIRES2-EGFP-HSP22 and 
cells transfected with vector only upon MG132 treatment (µM) (statistical analysis by 
ANOVA with Tukey’s test). Values are mean ± SEM of four samples. 
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It appeared that differentiated Neuro2a cells began to lose their neurite outgrowths 
after 24 h, perhaps due to the low serum concentrations of the media. Thus the 
experiment was repeated with 16 h of differentiation followed by treatment with 
MG132 so that both differentiation and treatment took place within 24 h. However, 
MTT results still indicated no statistically significant difference in viability of HSP22-
transfected differentiated Neuro2a cells when compared to control cells transfected 













Fig 4.10 Viability of transfected differentiated Neuro2a cells treated with MG132 
within 24 h of differentiation (µM/24 h). 
 
Neuro2a cells differentiated and treated with MG132 within 24 h of differentiation 
showed no statistically significant difference in viability (% of control) for HSP22-
transfected compared with control cells transfected with vector only (statistical 
analysis by ANOVA with Tukey’s test). Values are mean ± SEM of four samples.  
  
 
4.5.5 Measurement of % cell death of differentiated Neuro2a cells transfected 
with pIRES2-EGFP-HSP22 and pIRES2-EGFP vector only by flow cytometry 
Flow cytometry was also used to measure % cell death in the HSP22-transfected and 




















death was measured by calculating the percentage of cells in the sub-G1 peaks of the 
DNA histogram. Results however, showed no significant difference between cells 

























Fig 4.11 Percentage of cell death in transfected differentiated Neuro2a cells 
treated with MG132 (µM/24 h). 
 
Percentage of cell death in differentiated Neuro2a cells measured by flow cytometry 
showed no significant difference between HSP22-transfected cells and cells 
transfected with vector alone upon 24 h MG132 treatment (µM). Results obtained 
from one experiment.  
 
 
4.5.6 Confirmation of HSP22 expression in Neuro2a cells 
4.5.6.1 Using real-time RT-PCR 
Although the sequence of the pIRES2-EGFP-HSP22 plasmid was checked by DNA 
sequencing and restriction enzyme analysis (Section 4.3), the expression of HSP22 
was checked again using real-time RT-PCR to ensure that the lack of effect upon 
HSP22 upregulation was not due to a problem with the clone. The RNA of naïve 
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Neuro2a cells transfected with pIRES2-EGFP-HSP22 and pIRES2-EGFP vector only 
as well as untransfected control cells was extracted (Section 2.8.2) and the amount of 
HSP22 mRNA was measured by real-time RT-PCR (Section 2.12). Results showed an 
11.85-fold increase in HSP22 expression for the Neuro2a cells transfected with 
pIRES2-EGFP-HSP22 as compared to the untransfected control cells (Fig 4.12).  
 






















Fig 4.12 Relative expression of HSP22 in transfected Neuro2a cells. 
 
The relative expression of HSP22 in undifferentiated Neuro2a cells 24 h after 
transfection with vector only and pIRES2-EGFP-HSP22 as compared with 
untransfected control cells was measured by real-time RT-PCR. Values are mean ± 




4.5.6.2 Using Western blot analysis 
Western blot analysis using an anti-HSP22 antibody (Abcam) was also used to 
confirm the expression of HSP22 in transfected Neuro2a cells. Protein lysate from 
differentiated Neuro2a cells transfected with pIRES2-EGFP-HSP22 and vector only, 
both treated with 0.75 µM lactacystin for 24 h was analyzed. Results show an 
*
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increased expression of HSP22 in the HSP22-transfected cells as compared to the 
control cells transfected with vector only (Fig 4.13). This indicates that the pIRES2-
EGFP-HSP22 plasmid does express the desired HSP22 protein and the lack of effect 






Fig 4.13 Western blot analysis of HSP22 expression in transfected Neuro2a cells. 
 
Western blot analysis of 10 µg lysate of differentiated Neuro2a cells transfected with 
A. pIRES2-EGFP-HSP22 and B. pIRES2-EGFP vector only, both treated with 0.75 
µM lactacystin for 24 h. Representative results from three experiments. 
 
 
4.6 Effects of transient transfection of pIRES2-EGFP-HSP22 on SH-SY5Y cells 
4.6.1 SH-SY5Y cells 
Next SH-SY5Y cells were studied in a similar manner in order to find out if HSP22 
overexpression might have an effect on a different cell type. SH-SY5Y is a human 
catecholaminergic neuroblastoma cell line (Biedler et al., 1978). These cells have 
been shown to be useful in vitro models for the study of normal neurons (Willets et al., 
1993) and have also been employed in various studies to investigate neuronal death 
(Lai and Yu, 1997; Takahashi et al., 1997). In the undifferentiated state, SH-SY5Y 
cells have mitotic properties and do not display some features found in primary 
neurons. Thus retinoic acid has been used to stimulate differentiation of the cells to 
change the morphological, biochemical and functional properties to resemble those of 
mature neurons (Sidell, 1982). 
 
  A       B 
22 kDa 
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4.6.2 Viability of SH-SY5Y cells upon MG132 treatment 
Initial MTT tests were carried out to estimate the viability of undifferentiated and 
differentiated SH-SY5Y cells upon increasing concentrations of MG132 treatment. 
Results indicate that treatment of differentiated cells with 0.5 µM MG132 for 24 h 









Fig 4.14 Viability of naïve and differentiated SH-SY5Y cells treated with MG132 
(µM/24 h). 
 
Estimation of viability (% of control) of naïve and differentiated SH-SY5Y cells 
treated with increasing concentrations of MG132 for 24 h as compared to controls. 
Values are mean ± SEM of four samples. 
 
 
4.6.3 Viability of differentiated SH-SY5Y cells transfected with pIRES2-EGFP-
HSP22 and pIRES2-EGFP vector only upon MG132 treatment 
SH-SY5Y cells were seeded at 1.1 x 105 cells/ml as described in Section 2.2.1 and 
were transfected with either pIRES2-EGFP-HSP22 or vector only for 3 h before the 
medium was changed. The transfection efficiency was estimated to be about 30% 




















Germany). The cells were then differentiated as described in Section 2.2.2. After 24 h 
differentiation, the cells were treated with 0.1-0.75 µM MG132 for 24 h. This 
concentration range was chosen to cover a range of cell deaths from 10-50%, inferred 
from previous MTT measurements (Fig 4.14). Cell viabilities were then assessed 
using the MTT test (Section 2.4). Results as seen from Fig 4.15 indicate that there was 
no significant difference between the viability of cells transfected with pIRES2-













Fig 4.15 Viability of transfected differentiated SH-SY5Y cells treated with 
MG132 (µM/24 h). 
 
Differentiated SH-SY5Y cells treated with MG132 for 24 h showed no significant 
difference in viability (% of control) for cells transfected with pIRES2-EGFP-HSP22 
and control cells transfected with vector alone when measured by MTT test (statistical 
analysis by ANOVA with Tukey’s test). Values are mean ± SEM of four samples. 
 
 
As the SH-SY5Y cells were larger than Neuro2a cells, it was possible that they were 
too confluent to differentiate well under the cell confluency chosen, thus having 
insufficient differentiated cells at the time of treatment. The experiment was thus 




















cells/ml. MTT results after 24 h treatment with 0.1 µM MG132 however still 
indicated no significant difference between the cells transfected with pIRES2-EGFP-
























Fig 4.16 Viability of transfected differentiated SH-SY5Y cells at low confluency 
when treated with MG132 (µM/24 h). 
 
Differentiated SH-SY5Y cells at lower cell confluency treated with 0.1 µM MG132 
for 24 h showed no significant difference in viability (% of control) for cells 
transfected with pIRES2-EGFP-HSP22 and cells transfected with vector only when 
measured by MTT test (statistical analysis by ANOVA with Tukey’s test). Values are 
mean ± SEM of four samples. 
 
 
4.7 Effects of transient transfection of pIRES2-EGFP-HSP22 on PC12 cells 
4.7.1 PC12 cells  
Next the effect of transient transfection of pIRES2-EGFP-HSP22 on 
pheochromocytoma (PC12) cells was examined. These cells respond to nerve growth 
factor resulting in their acquisition of properties characteristic of sympathetic neurons, 
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with neurite extension and inhibition of proliferation (Greene and Tischler, 1976). 
The transfection efficiency of naïve PC12 cells was about 20-30 % as detected by the 








Fig 4.17 Differentiated PC12 cells transfected with pIRES2-EGFP-HSP22  
 
Differentiated PC12 cells had about 20% transfection efficiency based on EGFP 
expression. A: bright field image; B: FITC image. 
 
4.7.2 Viability of naïve PC12 cells upon treatment with MG132 
To find suitable concentrations of MG132 to challenge the transfected PC12 cells, 
untransfected naïve PC12 cells were first treated with proteasome inhibitor MG132 at 
increasing concentrations for 24 h. The MTT results are shown in Fig 4.18. Cells 
treated with 0.1 µM and 0.25 µM MG132 developed neurite extensions and did not 
appear to be undergoing cell injury based on microscopic observations. Thus the 
initial decrease in MTT A570 readings for cells treated at those concentrations might 
be due to the cells undergoing neuronal differentiation resulting in fewer cells 
compared to control which were still undergoing cell division. At higher 
A B
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concentrations of MG132 treatment, cell viability decreased significantly based on 




















Fig 4.18 Viability of naïve PC12 cells upon MG132 treatment (µM/24 h). 
 
Viability (% of control) of naïve PC12 cells treated with increasing concentrations of 




4.7.3 Viability of differentiated transfected PC12 cells treated with MG132 
Since differentiated PC12 cells are more susceptible to cell injury compared to naïve 
PC12 cells, 0.1 µM MG132 was used to treat the differentiated transfected PC12 cells. 
MTT results indicate that there was a statistically significant protection against loss of 
viability for cells transfected with pIRES2-EGFP-HSP22 compared to cells 
transfected with pIRES2-EGFP vector only after 0.25 µM MG132 treatment for 24 h 
(Fig 4.19). The increase was about 25% of the viability of vector-transfected cells of 

























Fig 4.19 Viability of transfected differentiated PC12 cells treated with MG132 
(µM/24 h). 
 
Viability (% of control) of differentiated PC12 cells showed statistically significant 
difference for cells transfected with pIRES2-EGFP-HSP22 vs cells transfected with 
vector only when treated for 24 h with 0.25 µM MG132. Values are mean ± SEM of 
three samples and *p<0.05 (ANOVA with Tukey’s test) compared with control. 
 
 
The PC12 cells for the above experiment were seeded at a higher cell density of 4.5 x 
105  cells/ml and appeared too confluent for maximal differentiation of the PC12 cells. 
Thus PC12 cells were seeded at a slightly lower confluency of 3.3 x 105 cells/ml in 
order to obtain more cell differentiation before treatment. The cells were treated at 0.1 
µM MG132 for a longer period of 48 h this time, in order to observe if there would be 
a significant difference in cell viability upon longer treatment duration. MTT results 

















Fig 4.20 Viability of transfected differentiated PC12 cells treated with 0.1 µM 
MG132 for 48 h. 
 
Viability (% of control) of differentiated PC12 cells seeded at 3.3 x 105 cells/ml and 
treated with 0.1 µM MG132 for 48 h showed a small but statistically significant 
difference between cells transfected with pIRES2-EGFP-HSP22 and control cells 
transfected with pIRES2-EGFP vector only. Values are mean ± SEM of four samples 




HSPs have been found to act as apoptosis regulatory proteins with both anti-apoptotic 
and pro-apoptotic activity (reviewed by Garrido et al., 2001). Many HSPs are anti-
apoptotic and are able to directly inhibit caspase activation. Examples from the sHSP 
family would include HSP27 and αB-crystallin. HSP27 is a stress inducible HSP and 
has been shown to bind to cytochrome c, after its release from the mitochondria as 
well as to procaspase 3, thus preventing the formation of the apoptosome (Bruey et al., 
2000; Pandey et al., 2000). αB-crystallin, on the other hand, inhibits apoptosis by 




















In this way, both the mitochondrial and death receptor pathways of apoptosis are 
inhibited by this sHSP (Kamradt et al., 2001).  
 
HSP22 was postulated to play a role in the regulation of proteasome inhibitor-
mediated apoptosis for several reasons. First, its increased expression was induced at 
the early time points of proteasome inhibition, indicating its potential role in response 
to cell stress. Also, this increase in HSP22 was found to be specific in response to 
proteasome inhibitor-mediated apoptosis in neurons (Fig 4.1) - other apoptosis-
inducing drugs did not cause a similar increase in HSP22 although the degree of cell 
injury was similar. This shows that HSP22 upregulation is unlikely to be a general 
response to cell death. Second, HSP22 has been found to interact with HSP27, a sHSP 
which confers resistance to apoptosis induced by a wide range of insults including 
oxidative stress, ligation of the Fas death receptor, growth factor deprivation, 
hyperthermia, UV radiation, cytotoxic drugs such as staurosporine and anticancer 
drugs (reviewed by Garrido et al., 2001). Thus it is possible that the binding of HSP22 
to this protein may modulate the activity of the protective HSP27. Moreover human 
HSP22 has been found to be most closely related to human HSP27 among the known 
members of this protein family (Benndorf et al., 2001) and hence may share a similar 
function in the regulation of apoptosis. Third, missense mutations in HSP22 have 
been shown to have a causal link with the human neuromuscular disorder distal 
hereditary motor neuropathy (Irobi et al., 2004). This indicates its important role in 
the biology of the motor neuron. Since the transcriptional and post-translational 
regulation of HSP27 has been found to be essential for sensory and motor neuron 
survival after peripheral nerve injury (Benn et al., 2002), the increased expression of 
its molecular partner HSP22 may also have a neuroprotective effect. 
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In this study an anti-apoptotic effect against proteasome inhibitors was observed for 
HSP22 (Fig 4.19 and 4.20) when overexpressed in PC12 cells under only one set of 
experimental conditions. This putative protective effect of HSP22 in PC12 cells was 
more apparent when greater cell injury was induced (Fig 4.19 and Fig 4.20). When 
cell viability was decreased to about 50% upon MG132 treatment, an increased 
relative viability of 25% was observed in the HSP22-transfected cells compared to the 
vector-transfected cells. However, there was no effect of HSP22 upregulation 
observed in Neuro2a and SH-SY5Y cells.  
 
The lack of effect of HSP22 expression on Neuro2a and SH-SY5Y cells could be due 
to several factors. In the case of SH-SY5Y cells, it has been found that retinoic acid-
treated SH-SY5Y cells take a longer time of about 3 days for the differentiating effect 
to be apparent and 6 days to have clearly elongated processes (Tieu et al., 1999) as 
compared to 1 day for Neuro2a and PC12 cells (Burry, 2001; Shea et al., 1985).  
During the period of initial differentiation, they continue to proliferate, even at a 
slightly increased rate (Tieu et al., 1999). After differentiation, they also appeared to 
be healthier than the naïve cells and better able to withstand severe cell toxicity (Fig 
4.14; Tieu et al., 1999). Thus by the time of treatment after 6 days of differentiation, 
the percentage of cells transfected with HSP22 would have decreased due to increase 
in number of cells, thus reducing any putative effect of HSP22 upregulation. The 
increase in survival of retinoic acid-treated SH-SY5Y cells towards various toxic 
insults have been found to be due to increased Bcl-2 (anti-apoptotic) and decreased 
p53 (pro-apoptotic) proteins in the cells upon differentiation (Tieu et al., 1999). It is 
possible that the above anti-apoptotic effects exceed the possible effects of HSP22, 
thus there is no observed difference upon HSP22 transfection.  
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sHSPs are known to be part of signal transduction cascades, with some of them being 
phosphoproteins (Benndorf et al., 2001). The increased expression of HSP27 in 
response to stress is preceded by a phosphorylation-induced reorganization of its 
native structure as a large oligomeric protein (reviewed by Concannon et al., 2003). 
HSP27 can be phosphorylated at three serine residues, Ser-15, Ser-78 and Ser-82 by 
MAPKAP kinases 2 and 3, and its phosphorylation enhances the formation of smaller 
tetrameric units (reviewed by Concannon et al., 2003).  The oligomerization/ 
phosphorylation status of HSP27 plays a critical role for cell survival under stress 
conditions. Thus perhaps in both Neuro2a and SH-SY5Y cells, the specific enzymes 
involved in the catalysis of the phosphorylation of HSP22 may not be present to 
regulate the formation of the complexes necessary for protective function. Another 
possibility would be that the cells do not contain other sHSPs or specific binding 
partners of HSP22 which would otherwise form hetero-oligomeric complexes that 
might result in a neuroprotective effect. While HSP22 has been found to be able to 
bind to itself as well as to three other sHSPs (cvHSP, MKBP and HSP27) (Sun et al., 
2004), the exact functions of these interactions and complexes formed are still 
unknown. Hence further studies in this area are necessary for a better understanding 
of the physiological function of HSP22.  
 
Initially the amount of differentiation of the cells was also hypothesized to play an 
important role in the effect of HSP22 upregulation. When cell differentiation was lost 
in Neuro2a cells perhaps due to the depletion of retinoic acid after 24 h, there was no 
observed difference in viability upon MG132 treatment for cells transfected with 
pIRES2-EGFP-HSP22 and cells transfected with vector only. Thus treatment while 
the cells were still well-differentiated (within 24 h of differentiation) was 
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administered with the postulation that the putative protective effect of HSP22 is likely 
to be specific towards neurons. However results for Neuro2a still indicated no 
protective effect by HSP22.  
 
While Neuro2a and SH-SY5Y cells had no increase in viability upon HSP22 
transfection, differentiated PC12 cells treated with MG132 had increased viability of 
up to 25% upon HSP22 transfection. One factor that might account for the relatively 
low increase of cell viability upon HSP22 upregulation in differentiated PC12 cells 
could be the low transfection efficiency. Transfection efficiency for PC12 cells ranged 
from 20-30% (Fig 4.17). Thus the overall protective effect of HSP22 would be diluted 
by lack of effect in the untransfected cells. Other techniques of transfection such as 
electroporation or the use of recombinant adenovirus to express the HSP22 transgene 
could be employed to obtain higher transfection efficiency so as to obtain more 
conclusive results in further studies. The use of a stably transfected neuronal cell line 
to study the effect of HSP22 upregulation would also be a better model system as all 
the cells would have increased HSP22 expression. This was not carried in this study 


















STUDY ON ANNEXIN A3 
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5. Study on annexin A3 
5.1 Introduction  
Annexin A3 (Anxa3) was another gene identified to be relatively highly increased in 
expression upon proteasome inhibition from the microarray study described in 
Chapter 3.  
 
Annexins are a distinct family of proteins that display Ca2+-dependent binding to 
phospholipids. While they have been implicated in various aspects of cell biology 
including initiation of membrane fusion in exocytosis and endocytosis, regulation of 
membrane trafficking, transmembrane channel activity, inhibition of phospholipase 
A2, inhibition of coagulation and transduction of mitogenic signals, their exact 
biological functions remain to be determined (Raynal and Pollard, 1994).  
 
All members of the annexin family possess a conserved structural element formed by 
four homologous repeats of about 70 residues and an N-terminal part that is variable 
in length and sequence (Gerke and Moss, 2002). The conserved core contains the Ca2+ 
and membrane binding sites while the N-terminal sequence is believed to be 
responsible for the specific functions of different annexins, containing 
phosphorylation sites in some annexins and in others, the site of interaction with other 
proteins (Gerke and Moss, 2002). Modifications of the N-terminal domain have been 
shown to influence the membrane-binding properties of the conserved core in Anxa3 
(Hofmann et al., 2000). 
 
Anxa3, also named lipocortin III or placental anticoagulant protein III (PAP III), has a 
molecular mass of 33 kDa with 322 amino acids. It contains a protein kinase C 
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phosphorylation site on its 16 residue long N-terminus and similar to its family 
members, demonstrates anticoagulant and anti-phospholipase A2 properties in vitro 
(Comera et al., 1990; Favier-Perron et al., 1996).  
 
Since there was a large increase in expression of the Anxa3 gene upon lactacystin 
treatment: 3.95 ± 0.2 fold after 24 h 0.5µM lactacystin, 11.1 ± 1.48 fold after 24 h 1 
µM lactacystin and 10.2 ± 0.95 fold after 48 h 1 µM lactacystin treatment, it was of 
interest to find out what functions, if any, this protein has in the regulation of 
apoptosis. This was further fuelled by the observation that the protein has been 
reported to possess anti-inflammatory properties (Comera et al., 1990). Moreover, no 
studies regarding its role in neuronal cells have been previously recorded.  
 
This chapter describes further studies done on the upregulation of Anxa3 upon various 
apoptotic insults, the cloning of a pIRES2-EGFP-Anxa3 clone and the effects of its 
upregulation in PC12 cell line. 
 
5.2 Anxa3 expression upon various drug treatments 
In order to find out if other insults triggered a similar upregulation of Anxa3, murine 
primary cortical neurons were treated with various drugs, using similar concentrations 
as has previously been shown to induce cell death by apoptosis- 0.5 µM STS (Koh et 
al., 1995), 1 µM colchicine (Bonfoco et al., 1995), 75 µM hydrogen peroxide (Cheung 
et al., 2000), 20 µM amyloid beta 1-40 (Loo et al., 1993), 0.1 µM MG132 (Qiu et al., 
2000) and 1 µM lactacystin (Cheung et al., 2004). Real-time RT-PCR was carried out 
and the results indicated that besides the proteasome inhibitors lactacystin and 
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MG132, which gave rise to a significant increase in Anxa3 levels, cell death induced 
by colchicine and hydrogen peroxide also resulted in an upregulation of Anxa3 (Fig 
5.1). Although about 50-70% of the cells in each treatment appeared injured based on 
their morphology, for STS and Aβ1-40 -treated cells, loss of viability did not lead to a 
significantly increased expression of Anxa3. This indicates that the upregulation of 
Anxa3, while not particularly specific towards proteasome inhibitor-mediated 






















Fig 5.1 Anxa3 expression upon various drug treatments (24 h). 
 
The expression of Anxa3 upon various drug treatments was investigated, resulting in 
lactacystin (Lac), MG132, colchicines (Colc) and hydrogen peroxide treatments with 
statistically significant upregulation. Values are mean ± SEM of three samples and 
*p<0.05 (ANOVA with Tukey’s test) compared with control. 
 
5.3 Generation of pIRES2-EGFP-Anxa3 clone 
The full length cDNA of mouse Anxa3 was PCR-amplified from RZPD Clone ID 
IRAKp961Q2 (RZPD German Resource Center for Genome Research, Berlin, 
Germany) using the forward primer TAAAGAGCTCATGGCCTCTATCTGGGTTG  
    ctr         0.5µM       1µM         0.1µM     0.25µM       1µM         75µM      20µM 








(Sac1 site underlined) and reversed primer TCATCAATCATCTTCTCCACAG. The 
DNA sequencing results showed that the clone was mostly similar to the mus 
musculus annexin A3 nucleotide sequence from National Center for Biotechnology 
Information (NCBI) (NM_013470) except at nucleotide 311 (resulting in no change 
of amino acid residue Asp), nucleotide 370 (resulting in change from Val to Ala), 
nucleotide 491 (resulting in change from Asn to Lys) and nucleotide 492 (resulting in 
change from Glu to Gln). The sequence cited in NCBI however has yet to be subject 
to NCBI final review and so the cloning of the resultant PCR amplicon into a 
pIRES2-EGFP vector (Clontech Laboratories Inc., Palo Alto, CA) using its Sac1 and 
SmaI sites (Fig 5.2) was continued. This vector enables Anxa3 to be expressed 
together with but not conjugated to the EGFP. The sequence was confirmed by DNA 
sequencing (refer to Appendix) and restriction enzyme analysis (Fig 5.3) using 





















Fig 5.2 Restriction map and multiple cloning site of pIRES2-EGFP vector, 
indicating restriction sites used for cloning pIRES2-EGFP-Anxa3. 
 
Restriction map and multiple cloning site of pIRES2-EGFP vector, with unique 
restriction sites in bold, and restriction sites used for cloning Anxa3 underlined 










Fig 5.3 Xho1 and BamHI restriction enzyme digestion of pIRES2-EGFP-Anxa3. 
 
Xho1 and BamHI restriction enzyme digestion of pIRES2-EGFP-Anxa3 showing 
correct size of products: ~5.3 kb for vector and ~900 bp for Anxa3 insert in Lane 3. 
Lane 1: 100 bp ladder; Lane2: 1 kb ladder. Results are representative of at least three 
experiments. 
 
5.4 Effects of transient transfection of pIRES2-EGFP-Anxa3 on PC12 cells 
Preliminary studies of the effects of transient transfection of pIRES2-EGFP-Anxa3 
were carried out on PC12 cells. The transfection efficiency of naïve PC12 cells was 






Fig 5.4 Differentiated PC12 cells transfected with pIRES2-EGFP-Anxa3.  
 
A: bright field image; B: FITC image. 
A B
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5.4.1 MTT test to estimate viability of differentiated PC12 cells transfected with 
pIRES2-EGFP-Anxa3 and pIRES2-EGFP vector only 
Treatment conditions of 0.1 and 0.25 µM MG132 were applied to the differentiated 
PC12 cells as the former concentration would cause cell injury of less than 50% while 
the latter would cause cell injury of about 50% as estimated from Fig 4.19. MTT 
results indicated no significant change in viability for pIRES2-EGFP-Anxa3 
transfected cells compared to cells transfected with pIRES2-EGFP vector only after 











Fig 5.5 Viability of transfected differentiated PC12 cells treated with MG132 
(µM/24 h). 
 
Viability (% of control) of differentiated PC12 cells measured by MTT test showed 
no significant difference between cells transfected with pIRES2-EGFP-Anxa3 and 
control cells transfected with vector only upon MG132 treatment (µM) for 24 h 




The PC12 cells for the above experiment were seeded at a density of 4.5 x 105 
cells/ml and appeared too confluent for maximal differentiation of the PC12 cells. 
When the PC12 cells were seeded at a confluency of 3.3 x 105 cells/ml in order to 



















significant difference in relative viability of cells transfected with pIRES2-EGFP-
Anxa3 compared with that of control cells transfected with vector only upon 48 h 0.1 
µM MG132 treatment (Fig 5.6). The Anxa3-transfected cells had a 20% higher 














Fig 5.6 Viability of transfected differentiated PC12 cells treated with 0.1 µM 
MG132 for 48 h. 
 
Viability (% of control) of differentiated PC12 cells seeded at 3.3 x 105 cells/ml and 
treated with 0.1 µM MG132 for 48 h showed a statistically significant difference 
between cells transfected with pIRES2-EGFP-Anxa3 and pIRES2-EGFP vector only 
plasmids. Values are mean ± SEM of three samples and *p<0.05 (ANOVA with 
Tukey’s test) compared with control. 
 
5.4.2 Measurement of caspase 3 activity of differentiated PC12 cells transfected 
with pIRES2-EGFP-Anxa3 and pIRES2-EGFP vector only 
As an additional marker to confirm the effect of overexpression of Anxa3 in 
differentiated PC12 cells, caspase 3 activity of the cells treated with 0.1 µM MG132 
for 24 h was measured as described in Section 2.25 These cells were differentiated for 
48 h instead of 24 h in order to ensure a maximal number of differentiated neuron-like 
cells before treatment. Results show that there is a statistically lower amount of 



















cells transfected with vector only (Fig 5.7). This suggests that there was 16.7% less 
neuronal apoptosis generated in the cells with overexpressed Anxa3 as compared to 
the vector-transfected control cells, thus confirming the results obtained from MTT 
measurements in Section 5.4.1 (Fig 5.6). 





























Fig 5.7 Caspase 3 activity of transfected differentiated PC12 cells. 
 
Differentiated PC12 cells transfected with pIRES2-EGFP-Anxa3 plasmid and treated 
with 0.1 µM MG132 for 24 h showed 16% less relative caspase 3 activity compared 
to similarly treated control cells transfected with pIRES2-EGFP vector only. Values 
are mean ± SEM of three samples and *p<0.05 (ANOVA with Tukey’s test) 
compared with control. 
 
 
5.5 Discussion  
This study was carried out to investigate the possible role of Anxa3 in the regulation 
of apoptosis in neuronal cells. Its function in response to cell stress was hypothesized 
due to its large increase in expression at the early time points of proteasome inhibition. 
However this large increase in expression was also observed at 48 h 1 µM lactacystin 
treatment (Fig 3.5) where more than 50% of the cells were undergoing apoptosis (Fig 
3.1). Thus to verify that the upregulation of Anxa3 is not a general phenomenon of 
apoptosis in neurons, its expression upon various apoptosis-inducing drug treatments 
*
             Control                                          0.1 µM MG132 
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was investigated. Results showed that Anxa3 was upregulated when cells were treated 
with proteasome inhibitors MG132 and lactacystin, as well as upon colchicine and 
hydrogen peroxide-induced cell death but not upon treatment with staurosporine or 
Aβ1-40 (Fig 5.1). This indicates that Anxa3 upregulation is unlikely to be a general 
response to cell death although it is not specific to proteasome inhibitor-mediated 
apoptosis. 
 
The degree of differentiation of the cells appeared to play an important role in the 
effect of Anxa3 upregulation. Increased expression of Anxa3 in PC12 cells that were 
less differentiated had no apparent effect against MG132-induced apoptosis while in 
well-differentiated PC12 cells, an approximately 20% increase in cell viability was 
observed when compared to vector-transfected cells (Figs 5.5, 5.6 and 5.7). This 
suggests that the putative protective effect of Anxa3 might be specific towards 
neurons. In a study on the differential expression of annexins I-VI in the rat dorsal 
root ganglia and spinal cord, it was found that Anxa3 is expressed by most sensory 
neurons in the dorsal root ganglia (Naciff et al., 1996). However the function of this 
annexin and its role in neurons in particular, is not clear and warrants further study. 
 
One possible method to further investigate the function of this gene is to make use of 
siRNA against the Anxa3 gene. This was not carried out here due to time constraints 
but it would be of interest to find out the effect of silencing Anxa3 in primary cortical 
neurons. Preliminary experiments were carried out to establish the siRNA technique 
in mouse primary cortical neurons and have shown that GFP-siRNA (Dharmacon) is 
able to be transfected into the cells, resulting in an approximately 80% decrease in 
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GFP expression upon pEGFP-N3 transfection (Fig 5.8). This shows that the 
transfection of siRNA into primary neuronal cells is a feasible method to silence 
specific gene expression and the method can be employed to better understand Anxa3 


















Fig 5.8  Western blot analysis demonstrating gene silencing of GFP using GFP-
siRNA transfection in murine primary cortical cells.  
 
Cells transfected with GFP-siRNA only had no GFP expression as expected while 
cells transfected with pEGFP-N3 expressed high levels of the 27 kDa GFP. After co-
transfection of GFP-siRNA, GFP expression decreased by 80-90%. Representative 
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6. Study on neoplastic progression 3 gene (Npn3) 
6.1 Introduction  
One gene identified to have relatively high levels of increased expression upon 
proteasome inhibition in murine cortical neurons is the neoplastic progression 3 gene 
(Npn3). A literature search indicated that there is no information regarding this gene 
at present. This chapter describes further studies done on the upregulation of Npn3 
upon various apoptotic insults and the process of inserting the Npn3 gene into a 
pIRES2-EGFP vector.  
 
6.2 Npn3 expression upon various drug treatments 
In order to find out if other insults triggered a similar upregulation of Npn3, murine 
primary cortical neurons were treated with various drugs which caused similar 
degrees of cell death based on morphological observation as described in Chapter 4.2. 
Real-time RT-PCR was carried out and the results indicated that besides the 
proteasome inhibitors lactacystin and MG132, which gave rise to a significant 
increase in Npn3 levels, cell death induced by hydrogen peroxide also resulted in an 
upregulation of Npn3 (Fig 6.1). This demonstrates that the upregulation of this gene is 





































Fig 6.1 Npn3 expression upon various drug treatments (24h). 
 
The expression of Npn3 upon various drug treatments was investigated, resulting in 
lactacystin (Lac), MG132 and hydrogen peroxide treatments with statistically 
significant upregulation. Values are mean ± SEM of three samples and *p<0.05 
(ANOVA with Tukey’s test) compared with control. 
 
6.3 Generation of pIRES2-EGFP-Npn3 clone 
Total RNA extracted from murine primary cortical neurons treated with 1 µM 
lactacystin for 24 h was reverse transcribed as described in Section 2.16. PCR 
amplification of the resulting cDNA was then carried out as described in Section 2.17, 
using the forward primer CCGGAATTCATGGGGCTACGCGCGGGTG  (EcoRI site 
underlined) and reversed primer CGCGGATCCCTACTATTGCAAGTCTGGTG 
TGGATGCTC (BamHI site underlined). After confirming the size of the PCR 
product, the amplicon was cloned into a pIRES2-EGFP vector (Clontech) using its 
EcoRI and BamHI sites (Fig 6.2). When the sequence of the resulting clone was 
checked by restriction enzyme digestion using BamHI and EcoRI however, results 
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Fig 6.2 Restriction map and multiple cloning site of pIRES2-EGFP vector, 
indicating restriction sites used for cloning pIRES2-EGFP-Npn3. 
 
Restriction map and multiple cloning site of pIRES2-EGFP vector, with unique 
restriction sites in bold, and restriction sites used for cloning Npn3 underlined 














Fig 6.3 Xho1 and BamHI restriction enzyme digestion of pIRES2-EGFP-Anxa3. 
 
Lane 1: EcoRI and BamHI restriction enzyme digest of putative pIRES2-EGFP-Npn3 
plasmid shows an extra band at 650 bp; Lane 2: 100 bp DNA ladder. Results are 
representative of at least 3 independent experiments. 
 
  Lane 1          2 
~ 650 bp 
 
~ 430 bp 
500 bp band of 
100 bp DNA 
ladder 
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The DNA sequencing results showed that the first 93 nucleotides of the Npn3 insert 
were missing or different from the mus musculus Npn3 nucleotide sequence from 
National Center for Biotechnology Information (NCBI) (NM_029688) (refer to 
Appendix). 
 
A further attempt to clone this gene was not carried out due to limitations of time.  
 
 
6.4 Discussion  
This clone was not successful due to unknown reasons and the procedure was not 
repeated due to time constraints. Further efforts to clone this gene and to explore its 
possible role in the regulation of neuronal apoptosis would be of interest due to the 
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7. General discussion and future work 
In this study, the effects of proteasome inhibition on neuronal cells were investigated.  
Differentially expressed genes upon lactacystin treatment were identified from a 
microarray study and further work was carried out on three selected genes, HSP22, 
Anxa3 and Npn3. 
 
The microarray analysis identified 228 differentially expressed genes involved in 
various functions such as the UPS, cell cycle regulation, apoptosis and oxidative 
stress upon lactacystin-induced proteasome inhibition. One difficulty faced in the 
analysis of the differentially expressed genes was how to distinguish between genes 
that were upregulated in response to cell death and those that were in response to 
proteasome inhibition, if such a distinction could be made. For this study, it was 
hypothesized that genes upregulated at the early time points but not at the later time 
point of 48 h when more than 50% of the cells were undergoing apoptosis were likely 
to be involved in anti-apoptotic stress response. This could be further verified by 
studying samples treated with even lower, subtoxic doses of proteasome inhibitors 
such that there is minimal cell death and also by comparing the effects of different 
proteasome inhibitors on the cells. In this way, specific genes differentially expressed 
due to proteasome inhibition rather than apoptosis could possibly be identified more 
clearly.  
 
Out of the three genes chosen for further study, HSP22 and Anxa3 both were shown 
to have a small neuroprotective effect against proteasome inhibitor-mediated 
apoptosis under some conditions. As the increased expression of HSP22 and Anxa3 
was relatively specific towards proteasome inhibitor-mediated apoptosis, it is likely 
121 
that both genes play a role in the regulation of neuronal cell death due to proteasome 
inhibition. Further studies to confirm their neuroprotective role through the use of 
gene silencing techniques as well as stably-transfected cell lines would be useful. 
Previous studies on both genes in neurons or neuronal cell lines are limited and hence 
more work is required to better understand their functions in these cells. 
 
Npn3 which was identified in this study to be highly expressed upon proteasome 
inhibition was not successfully cloned here. However further efforts to clone and 
study the effects of this gene in neurons would be of interest as so far there are no 
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